<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Endocr Soc</journal-id><journal-id journal-id-type="iso-abbrev">J Endocr Soc</journal-id><journal-id journal-id-type="pmc-domain-id">3254</journal-id><journal-id journal-id-type="pmc-domain">jes</journal-id><journal-id journal-id-type="publisher-id">jes</journal-id><journal-title-group><journal-title>Journal of the Endocrine Society</journal-title></journal-title-group><issn pub-type="epub">2472-1972</issn><publisher><publisher-name>The Endocrine Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC9760550</article-id><article-id pub-id-type="pmcid-ver">PMC9760550.1</article-id><article-id pub-id-type="pmcaid">9760550</article-id><article-id pub-id-type="pmcaiid">9760550</article-id><article-id pub-id-type="pmid">36545644</article-id><article-id pub-id-type="doi">10.1210/jendso/bvac185</article-id><article-id pub-id-type="publisher-id">bvac185</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Mini-Review</subject></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/MED00250</subject></subj-group></article-categories><title-group><article-title>Perioperative Evaluation and Management of Patients on Glucocorticoids</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7719-4729</contrib-id><name name-style="western"><surname>Chen Cardenas</surname><given-names initials="SM">Stanley M</given-names></name><aff>
<institution>Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine</institution>, <addr-line>Baltimore, MD 21287</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4822-2705</contrib-id><name name-style="western"><surname>Santhanam</surname><given-names initials="P">Prasanna</given-names></name><aff>
<institution>Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine</institution>, <addr-line>Baltimore, MD 21287</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9751-8687</contrib-id><name name-style="western"><surname>Morris-Wiseman</surname><given-names initials="L">Lilah</given-names></name><aff>
<institution>Division of Endocrine Surgery, Department of Surgery, Johns Hopkins University School of Medicine</institution>, <addr-line>Baltimore, MD 21287</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6495-2244</contrib-id><name name-style="western"><surname>Salvatori</surname><given-names initials="R">Roberto</given-names></name><aff>
<institution>Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine</institution>, <addr-line>Baltimore, MD 21287</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8832-9385</contrib-id><name name-style="western"><surname>Hamrahian</surname><given-names initials="AH">Amir H</given-names></name><aff>
<institution>Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine</institution>, <addr-line>Baltimore, MD 21287</addr-line>, <country country="US">USA</country></aff><xref rid="bvac185-cor1" ref-type="corresp"/><email>ahamrah1@jmhi.edu</email></contrib></contrib-group><author-notes><corresp id="bvac185-cor1"><bold>Correspondence:</bold> Amir Hamrahian, MD, Division of Endocrinology, Diabetes, and Metabolism, Johns Hopkins University School of Medicine, 1830 E Monument St, Ste 333, Baltimore, MD 21287, USA. Email: <email>ahamrah1@jmhi.edu</email>.</corresp></author-notes><pub-date pub-type="collection"><month>2</month><year>2023</year></pub-date><pub-date pub-type="epub" iso-8601-date="2022-12-02"><day>02</day><month>12</month><year>2022</year></pub-date><volume>7</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">488040</issue-id><elocation-id>bvac185</elocation-id><history><date date-type="received"><day>29</day><month>9</month><year>2022</year></date><date date-type="editorial-decision"><day>29</day><month>11</month><year>2022</year></date><date date-type="corrected-typeset"><day>19</day><month>12</month><year>2022</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>12</month><year>2022</year></date></event><event event-type="pmc-live"><date><day>20</day><month>12</month><year>2022</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-05-07 13:25:27.437"><day>07</day><month>05</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society.</copyright-statement><copyright-year>2022</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="bvac185.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bvac185.pdf"/><abstract><title>Abstract</title><p>Myriad questions regarding perioperative management of patients on glucocorticoids (GCs) continue to be debated including which patients are at risk for adrenal insufficiency (AI), what is the correct dose and duration of supplemental GCs, or are they necessary for everyone? These questions remain partly unanswered due to the heterogeneity and low quality of data, studies with small sample sizes, and the limited number of randomized trials. To date, we know that although all routes of GC administration can result in hypothalamic-pituitary-adrenal (HPA) axis suppression, perioperative adrenal crisis is rare. Correlation between biochemical testing for AI and clinical events is lacking. Some of the current perioperative management recommendations based on daily GC dose and duration of therapy may be difficult to follow in clinical practice. The prospective and retrospective studies consistently report that continuing the daily dose of GCs perioperatively is not associated with a higher risk for adrenal crises in patients with GC-induced AI. Considering that oral GC intake may be unreliable in the early postoperative period, providing the daily GC plus a short course of IV hydrocortisone 25 to 100&#8197;mg per day based on the degree of surgical stress seems reasonable. In patients who have stopped GC therapy before surgery, careful assessment of the HPA axis is necessary to avoid an adrenal crisis. In conclusion, our literature review indicates that lower doses and shorter duration of supplemental GCs perioperatively are sufficient to maintain homeostasis. We emphasize the need for well-designed randomized studies on this frequently encountered clinical scenario.</p></abstract><kwd-group><kwd>perioperative evaluation</kwd><kwd>perioperative management</kwd><kwd>glucocorticoids</kwd><kwd>hypothalamic-pituitary-adrenal axis suppression</kwd><kwd>glucocorticoid-induced adrenal insufficiency</kwd><kwd>adrenal crisis</kwd></kwd-group><counts><page-count count="16"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>Glucocorticoids (GCs) are one of the most commonly prescribed drugs with an estimated use prevalence of approximately 1% of the US population [<xref rid="bvac185-B1" ref-type="bibr">1</xref>]. They are very effective anti-inflammatory medications and considered first-line treatment for many autoimmune conditions. One important consequence of supraphysiological and/or long-term GC treatment is the potential for hypothalamic-pituitary-adrenal (HPA) axis suppression leading to GC-induced adrenal insufficiency (AI), which is associated with increased morbidity and mortality [<xref rid="bvac185-B2" ref-type="bibr">2</xref>]. When associated with a stressor such as a surgical procedure, HPA axis suppression can result in adrenal crisis. This outcome was recognized in early-20th-century studies when adrenalectomized dogs experienced circulatory shock after laparotomy that could be prevented by administering GCs [<xref rid="bvac185-B3" ref-type="bibr">3</xref>, <xref rid="bvac185-B4" ref-type="bibr">4</xref>]. In the 1950s, multiple reports described patients on chronic GC therapy for rheumatoid arthritis who died shortly after orthopedic surgery. Postmortem examinations consistently revealed bilateral adrenal atrophy, leading to the conclusion that the adrenal glands&#8217; inability to respond to surgical stress was the cause of death [<xref rid="bvac185-B5" ref-type="bibr">5&#8211;7</xref>]. The resultant concern about postoperative adrenal crisis in patients on GCs led to the routine use of high-dose perioperative GC replacement in clinical practice.</p><p>Currently, there is little high-quality evidence supporting routine perioperative use of high-dose GCs [<xref rid="bvac185-B8" ref-type="bibr">8&#8211;11</xref>]. While underdosing perioperative GCs may place patients at risk for cardiovascular collapse, high doses carry a risk of hyperglycemia, hypertension, opportunistic infections, bone loss in a state of immobility, venous thromboembolism, and poor wound healing [<xref rid="bvac185-B12" ref-type="bibr">12&#8211;14</xref>]. This review outlines the key physiologic aspects of the stress response to surgery, the effect of different forms of GCs on the HPA axis, the evidence for perioperative GC administration, and our personalized approach to perioperative management in adults with GC-induced AI.</p><sec id="bvac185-s0"><title>Regulation of the HPA Axis Perioperatively</title><p>The HPA axis is regulated by the classic negative feedback of cortisol as well as other neurohumoral inputs including vasopressin, the autonomic nervous system, inflammation, and opioids (<xref rid="bvac185-F1" ref-type="fig">Fig. 1</xref>). This results in an estimated production of about 5.7&#8197;mg/m<sup>2</sup> or 9.9&#8197;mg of cortisol per day in healthy adults which could increase to &gt;100&#8197;mg during times of major stress [<xref rid="bvac185-B8" ref-type="bibr">8</xref>, <xref rid="bvac185-B15" ref-type="bibr">15&#8211;17</xref>]. In plasma, the majority of cortisol (approximately 90%) binds tightly to corticosteroid-binding globulin (CBG) and loosely to albumin (&#8764;5%); the remaining (&#8764;5%) is the active, free fraction [<xref rid="bvac185-B18" ref-type="bibr">18</xref>, <xref rid="bvac185-B19" ref-type="bibr">19</xref>]. Free cortisol binds to the glucocorticoid receptors in the target cell's cytoplasm. After glucocorticoids bind to its receptor, this complex translocates to the nucleus regulating the transcription, inducing or repressing a multitude of genes [<xref rid="bvac185-B20" ref-type="bibr">20</xref>]. Glucocorticoid receptors are ubiquitously distributed in the body, including the hypothalamus and pituitary, where cortisol exerts a negative feedback [<xref rid="bvac185-B21" ref-type="bibr">21</xref>]. Other rapid, nongenomic effects have been recognized over the past decades. Known mechanisms thought to mediate these actions include GC interaction with nonspecific cellular membrane receptors, cytosolic GC receptor mediating nongenomic effects, and membrane-bound GC receptors [<xref rid="bvac185-B22" ref-type="bibr">22</xref>]. These nongenomic effects can involve activation of distinct signaling pathways that includes cAMP, with activation of multiple kinases, increase in intracellular calcium concentrations; as well as intracellular receptors that targets mitochondrial gene expression, all of these with a recognized tissue specificity [<xref rid="bvac185-B23" ref-type="bibr">23</xref>]. These nongenomic mechanisms of action are highly relevant in the development of new drugs with higher selectivity and better side-effect profile compared to the classic GCs targeting the genomic actions.</p><fig position="float" id="bvac185-F1" fig-type="figure" orientation="portrait"><label>Figure 1.</label><caption><p>The hypothalamic-pituitary-adrenal axis regulation [<xref rid="bvac185-B24" ref-type="bibr">24&#8211;27</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="bvac185f1.jpg"/></fig><p>Cortisol's actions are further regulated by enzymatic transformation of its active and inactive forms. In the kidney, colon, salivary glands, and placenta, 11-&#946;-hydroxysteroid dehydrogenase type 2 inactivates cortisol into cortisone, protecting these tissues from overstimulation of the mineralocorticoid receptor. In most other tissues, but mainly in the liver, 11-&#946;-hydroxysteroid dehydrogenase type 1 converts cortisone into cortisol, augmenting the GC effects when needed [<xref rid="bvac185-B28" ref-type="bibr">28</xref>].</p><p>Multiple factors determine the degree of HPA axis activation during a surgical procedure. Individual factors, including genetics, age, sex, comorbidities, and medications, as well as perioperative factors, such as type and duration of anesthesia and operative procedure and perioperative complications, contribute to the heterogeneity seen in studies evaluating the HPA axis response [<xref rid="bvac185-B29" ref-type="bibr">29</xref>].</p><p>Different types of surgical procedures generate different degrees of HPA axis activation [<xref rid="bvac185-B29" ref-type="bibr">29&#8211;31</xref>]. Criteria to stratify the degree of surgical risk (Grade I-III), independent from the anesthetic risk, are summarized in <xref rid="bvac185-T1" ref-type="table">Table 1</xref> [<xref rid="bvac185-B32" ref-type="bibr">32</xref>]. Multiple studies including a systematic review and meta-analysis of 71 studies including 2953 patients show that cortisol levels increase in proportion to the grade of surgery [<xref rid="bvac185-B29" ref-type="bibr">29&#8211;31</xref>, <xref rid="bvac185-B33" ref-type="bibr">33</xref>, <xref rid="bvac185-B34" ref-type="bibr">34</xref>]. In Grade I procedures, no intraoperative cortisol peak is observed, whereas in Grade II procedures, peak cortisol occurs at the time of extubation and returns to baseline at 24&#8197;hours [<xref rid="bvac185-B29" ref-type="bibr">29</xref>, <xref rid="bvac185-B30" ref-type="bibr">30</xref>]. With Grade III procedures, peak cortisol occurs 6 to 18&#8197;hours postoperatively, persists for 24&#8197;hours, and returns to baseline by postoperative day 5 to 7 [<xref rid="bvac185-B29" ref-type="bibr">29&#8211;31</xref>, <xref rid="bvac185-B33" ref-type="bibr">33</xref>, <xref rid="bvac185-B34" ref-type="bibr">34</xref>]. Therefore, the maximum activation of the HPA axis occurs within the first 24&#8197;hour postoperatively, returning to baseline in &lt;7 days even in patients undergoing Grade III operations [<xref rid="bvac185-B35" ref-type="bibr">35</xref>, <xref rid="bvac185-B36" ref-type="bibr">36</xref>].</p><table-wrap position="float" id="bvac185-T1" orientation="portrait"><label>Table 1.</label><caption><p>
<bold>Surgical stress associated with common surgical procedures, based on the modified Johns Hopkins surgical criteria [</bold>
<xref rid="bvac185-B32" ref-type="bibr">32</xref>
<bold>]</bold>
</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Grade</th><th align="left" rowspan="1" colspan="1">General Characteristics</th><th align="left" rowspan="1" colspan="1">Characteristic Operations</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Grade I<break/>(Minor)</td><td rowspan="1" colspan="1">Minimal to mild risk independent of anesthesia<break/>Minimal to moderately invasive procedure<break/>Potential blood loss of &lt; 500&#8197;mL</td><td rowspan="1" colspan="1">Minor general surgical procedures (skin/subcutaneous tissue procedures, inguinal hernia repair, breast biopsy)<break/>Endoscopy (including cystoscopy, hysteroscopy, bronchoscopy, minor laparoscopy, arthroscopy)<break/>Minor gynecologic procedures (tubal ligation, dilation, and curettage)<break/>Minor otolaryngology procedures (myringotomy tubes, tonsillectomy/rhinoplasty)</td></tr><tr><td rowspan="1" colspan="1">Grade II<break/>(Moderate)</td><td rowspan="1" colspan="1">Moderate risk independent of anesthesia<break/>Moderately to significantly invasive procedures<break/>Potential blood loss of 500-1500&#8197;mL</td><td rowspan="1" colspan="1">Open or laparoscopic resection/reconstruction of the digestive tract; cholecystectomy<break/>Thyroidectomy<break/>Cystectomy, nephrectomy<break/>Hysterectomy or myomectomy<break/>Laminectomy<break/>Joint replacement</td></tr><tr><td rowspan="1" colspan="1">Grade III<break/>(Major)</td><td rowspan="1" colspan="1">Major to critical risk independent of anesthesia<break/>Highly invasive procedure<break/>Potential blood loss &gt;1500&#8197;mL<break/>Usual postoperative intensive care unit stay with invasive monitoring</td><td rowspan="1" colspan="1">Any major orthopedic-spinal, oropharyngeal, or genitourinary repair or reconstruction<break/>Any intracranial, major vascular, or cardiothoracic procedure</td></tr></tbody></table></table-wrap><p>To understand the perioperative HPA axis response, Udelsman et al measured blood samples every 10&#8197;minutes during and after Grade II neck operations performed with identical sedation and anesthetic regimens. Interestingly, CRH, ACTH, and cortisol levels were unchanged intraoperatively. However, there was a marked elevation in ACTH and cortisol levels during anesthetic reversal, endotracheal extubation, and immediately postoperatively [<xref rid="bvac185-B37" ref-type="bibr">37</xref>]. In contrast, in Grade III operations, cortisol remained elevated on postoperative day 2, but there was a marked reduction in CRH and ACTH levels [<xref rid="bvac185-B38" ref-type="bibr">38</xref>]. A recently reported significant decrease in cortisol clearance during critical illness could explain this postoperative day 2 dissociation between CRH/ACTH and cortisol levels through negative feedback [<xref rid="bvac185-B39" ref-type="bibr">39</xref>]. Furthermore, neural regulation of the HPA axis seem to have an important role in the modulating the stress response to surgical procedures. Studies showing that epidural or local anesthesia can interrupt HPA axis activation following a surgical incision highlight its role [<xref rid="bvac185-B40" ref-type="bibr">40</xref>, <xref rid="bvac185-B41" ref-type="bibr">41</xref>]. Also, the sympathetic nerves of the adrenal cortex can facilitate the ACTH response [<xref rid="bvac185-B42" ref-type="bibr">42</xref>].</p><p>In addition to an increase in cortisol secretion, immediately postoperatively there is an approximately 30% to 50% decrease in CBG, and this reduction persists at 24&#8197;hours after surgery, resulting in elevated free cortisol levels [<xref rid="bvac185-B43" ref-type="bibr">43</xref>, <xref rid="bvac185-B44" ref-type="bibr">44</xref>]. This increment in free cortisol could be associated with inflammation, given that interleukin-6 decreases CBG concentration by about half and the affinity of CBG for cortisol is reduced by neutrophil activation and fever, both common perioperatively [<xref rid="bvac185-B18" ref-type="bibr">18</xref>, <xref rid="bvac185-B45" ref-type="bibr">45</xref>].</p></sec><sec id="bvac185-s1"><title>Perioperative Symptoms of Adrenal Insufficiency and Cardiovascular Collapse</title><p>GCs have an essential role in the regulation of vascular tone, cardiac, and adrenomedullary function. In blood vessels, they have a permissive role in the action of vasoactive substances, particularly catecholamines [<xref rid="bvac185-B46" ref-type="bibr">46</xref>, <xref rid="bvac185-B47" ref-type="bibr">47</xref>]. Additionally, GCs promote vasoconstriction by inhibiting endothelial production of nitric oxide and prostacyclin [<xref rid="bvac185-B17" ref-type="bibr">17</xref>, <xref rid="bvac185-B47" ref-type="bibr">47</xref>], upregulating angiotensin II receptor AT1 [<xref rid="bvac185-B48" ref-type="bibr">48</xref>] as well as increasing &#945;-1 adrenergic receptors and norepinephrine-binding affinity in the vascular smooth muscle cells [<xref rid="bvac185-B47" ref-type="bibr">47</xref>, <xref rid="bvac185-B49" ref-type="bibr">49</xref>]. Accordingly, during an adrenal crisis, there is a markedly reduced vascular tone resulting in hypotension that can eventually become refractory to vasopressors.</p><p>In the heart, GCs increase contractility by increasing the expression of genes that regulate intracellular calcium concentrations [<xref rid="bvac185-B50" ref-type="bibr">50</xref>]. Studies in AI reported reduced stroke volume and cardiac index with increased systemic arterial resistance independent of changes in serum sodium and potassium levels [<xref rid="bvac185-B51" ref-type="bibr">51</xref>, <xref rid="bvac185-B52" ref-type="bibr">52</xref>]. Additionally, AI has been associated with high-output heart failure that can resemble the septic shock-associated loss of vascular tone [<xref rid="bvac185-B52" ref-type="bibr">52</xref>, <xref rid="bvac185-B53" ref-type="bibr">53</xref>]. These 2 hemodynamic profiles associated with hypotension depends on the degree of fluid resuscitation and the time the right heart catheterization is performed [<xref rid="bvac185-B52" ref-type="bibr">52</xref>]. Patients with AI may have prolongation of the PR interval, which can reach a first-degree AV block or worsen the underlying AV conduction abnormalities [<xref rid="bvac185-B54" ref-type="bibr">54</xref>]. These effects on cardiac output and the conduction system in AI can be reversed by GC replacement [<xref rid="bvac185-B55" ref-type="bibr">55&#8211;57</xref>].</p><p>Adrenal medullary development and function are highly dependent on the presence of adequate amounts of cortisol [<xref rid="bvac185-B58" ref-type="bibr">58</xref>, <xref rid="bvac185-B59" ref-type="bibr">59</xref>]. The expression and activity of phenylethanolymine N-methyltransferase, the enzyme that converts norepinephrine into epinephrine, requires a high intra-adrenal cortisol concentration that is maintained by the adrenoportal system between the cortex and the medulla [<xref rid="bvac185-B60" ref-type="bibr">60</xref>]. Glucocorticoids also inhibit catechol-O-methyl-transferase, resulting in decreased clearance of epinephrine [<xref rid="bvac185-B47" ref-type="bibr">47</xref>]. Therefore, the adrenomedullary function can become severely compromised in AI with markedly low levels of epinephrine at baseline and incomplete response during stress [<xref rid="bvac185-B61" ref-type="bibr">61</xref>].</p><p>Beyond cardiovascular instability and collapse, the symptoms of AI in the perioperative period can be subtle and may be missed due to their similarity to common postoperative complaints including anorexia, fatigue, nausea, vomiting, abdominal pain, muscle cramps, weakness, dizziness, and lethargy [<xref rid="bvac185-B62" ref-type="bibr">62</xref>]. The clinical team must be aware of GC withdrawal symptoms that may occur in patients on chronic GC on a fast perioperative taper; these patients who may experience AI-type symptoms despite being maintained on supraphysiological GC doses [<xref rid="bvac185-B63" ref-type="bibr">63</xref>, <xref rid="bvac185-B64" ref-type="bibr">64</xref>].</p></sec><sec id="bvac185-s2"><title>The HPA Axis in Patients Using Glucocorticoids</title><sec id="bvac185-s2.1"><title>Pharmacological Properties of Glucocorticoids</title><p>Glucocorticoids have historically been classified as short, intermediate, and long-acting according to their biological half-life (<xref rid="bvac185-T2" ref-type="table">Table 2</xref>). However, GCs have many other variable pharmacologic properties, including administration route, potency, and affinity for the GC receptor, resulting in a heterogeneous group of drugs with different potentials to suppress the HPA axis.</p><table-wrap position="float" id="bvac185-T2" orientation="portrait"><label>Table 2.</label><caption><p>
<bold>Pharmacological properties of frequently used glucocorticoids [</bold>
<xref rid="bvac185-B65" ref-type="bibr">65&#8211;68</xref>
<bold>]</bold>
</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Classification</th><th align="left" rowspan="1" colspan="1">Equivalent Glucocorticoid Dose (mg)</th><th align="left" rowspan="1" colspan="1">Glucocorticoid Activity</th><th align="left" rowspan="1" colspan="1">Mineralocorticoid Activity</th><th align="left" rowspan="1" colspan="1">Biological Half-Life (hours)</th><th align="left" rowspan="1" colspan="1">Plasma Half- Life (hours)</th><th align="left" rowspan="1" colspan="1">Bound in Plasma (%)</th></tr></thead><tbody><tr><td colspan="7" rowspan="1">Short Acting</td></tr><tr><td rowspan="1" colspan="1">&#8195;Hydrocortisone</td><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">8-12</td><td rowspan="1" colspan="1">1.3-2.3</td><td rowspan="1" colspan="1">90</td></tr><tr><td rowspan="1" colspan="1">&#8195;Cortisone acetate</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">0.8</td><td rowspan="1" colspan="1">0.8</td><td rowspan="1" colspan="1">8-12</td><td rowspan="1" colspan="1">0.5</td><td rowspan="1" colspan="1">&#8212;</td></tr><tr><td rowspan="1" colspan="1">&#8195;Deflazacort</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">&lt;12</td><td rowspan="1" colspan="1">1.3-1.9</td><td rowspan="1" colspan="1">40</td></tr><tr><td colspan="7" rowspan="1">Intermediate-Acting</td></tr><tr><td rowspan="1" colspan="1">&#8195;Prednisone</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">0.8</td><td rowspan="1" colspan="1">12-36</td><td rowspan="1" colspan="1">2-4</td><td rowspan="1" colspan="1">75</td></tr><tr><td rowspan="1" colspan="1">&#8195;Prednisolone</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">0.8</td><td rowspan="1" colspan="1">12-36</td><td rowspan="1" colspan="1">2-4</td><td rowspan="1" colspan="1">95</td></tr><tr><td rowspan="1" colspan="1">&#8195;Methylprednisolone</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">0.5</td><td rowspan="1" colspan="1">12-36</td><td rowspan="1" colspan="1">2-4</td><td rowspan="1" colspan="1">78</td></tr><tr><td rowspan="1" colspan="1">&#8195;Triamcinolone</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">Negligible</td><td rowspan="1" colspan="1">12-36</td><td rowspan="1" colspan="1">0.5</td><td rowspan="1" colspan="1">68</td></tr><tr><td colspan="7" rowspan="1">Long-Acting</td></tr><tr><td rowspan="1" colspan="1">&#8195;Betamethasone</td><td rowspan="1" colspan="1">0.6</td><td rowspan="1" colspan="1">25-30</td><td rowspan="1" colspan="1">Negligible</td><td rowspan="1" colspan="1">36-72</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">64</td></tr><tr><td rowspan="1" colspan="1">&#8195;Dexamethasone</td><td rowspan="1" colspan="1">0.375-0.75</td><td rowspan="1" colspan="1">30-40</td><td rowspan="1" colspan="1">Negligible</td><td rowspan="1" colspan="1">36-72</td><td rowspan="1" colspan="1">3.5-5</td><td rowspan="1" colspan="1">68</td></tr></tbody></table></table-wrap><p>In general, the absorption rate after oral administration is rapid (30-45&#8197;minutes) and similar among different preparations with bioavailability ranging from 60% to almost 100% [<xref rid="bvac185-B69" ref-type="bibr">69</xref>,70]. Intramuscular absorption is rapid, whereas the absorption after subcutaneous injections is slightly slower depending on the amount of adipose tissue present [<xref rid="bvac185-B71" ref-type="bibr">71</xref>]. Systemic absorption from other formulations such as inhaled, topical, ophthalmic, buccal, or rectal administration is lower, but all can potentially suppress the HPA axis [<xref rid="bvac185-B72" ref-type="bibr">72</xref>]. Topical and mucosal absorption of GCs depends on the integrity of the skin/epithelial barrier, which is modified by inflammation and influenced by the thickness of skin [<xref rid="bvac185-B72" ref-type="bibr">72</xref>]. Certain GCs such as Triamcinolone after intra-articular and epidural injection are slowly absorbed resulting in sustained supraphysiological concentration. Oral budesonide has a high first-pass effect in the liver where about 90% is inactivated. Despite this, HPA axis suppression and cases of adrenal crises have been reported [<xref rid="bvac185-B73" ref-type="bibr">73</xref>, <xref rid="bvac185-B74" ref-type="bibr">74</xref>].</p></sec><sec id="bvac185-s2.2"><title>Incidence of Postoperative Adrenal Insufficiency</title><p>Postoperative AI in patients on chronic GCs is rare [<xref rid="bvac185-B8" ref-type="bibr">8</xref>, <xref rid="bvac185-B17" ref-type="bibr">17</xref>, <xref rid="bvac185-B75" ref-type="bibr">75</xref>]. However, establishing the true incidence is challenging. In many cases, hypotension that resolves in response to GCs, in the absence of an alternative explanation, has been used as the criteria to establish the diagnosis of AI. A 1994 review of 57 cases of patients on chronic GCs who died possibly from postoperative adrenal crisis found confirmation in only 3 cases [<xref rid="bvac185-B8" ref-type="bibr">8</xref>]; this and other reports [<xref rid="bvac185-B33" ref-type="bibr">33</xref>, <xref rid="bvac185-B76" ref-type="bibr">76</xref>] indicate that post-op AI may not be as common as initially thought. In some instances, alternative etiologies such as major blood loss, anaphylaxis, or sepsis could have explained the postoperative hypotension. However, the incidence of postoperative AI may be underreported since reporting such statistics may be undesirable for hospitals. There is a clear need for further studies in this subject.</p></sec><sec id="bvac185-s2.3"><title>Risk for HPA Axis Suppression in Different Clinical Scenarios</title><p>The risk for HPA axis suppression in relation to GC exposure depends on multiple factors including the type of GC, ability of the drug to reach the systemic circulation, dose, and duration of treatment. However, the exact dose and duration that results in clinically significant AI has been a matter of debate [<xref rid="bvac185-B64" ref-type="bibr">64</xref>, <xref rid="bvac185-B77" ref-type="bibr">77&#8211;80</xref>]. In general, systemic treatments, long-acting GCs, higher doses, longer duration of therapy, higher potency, nighttime administration, multiple cycles of treatment, and multiple daily doses carry a higher risk for HPA axis suppression and AI [<xref rid="bvac185-B64" ref-type="bibr">64</xref>, <xref rid="bvac185-B77" ref-type="bibr">77&#8211;82</xref>]. Cushingoid features should alert clinicians of the presence of HPA suppression. Stopping chronic GCs close to an operation may have a significant impact on the risk for postoperative AI. Regardless, there is a poor correlation between biochemical HPA axis suppression and clinical outcome (AI) [<xref rid="bvac185-B77" ref-type="bibr">77&#8211;80</xref>, <xref rid="bvac185-B83" ref-type="bibr">83</xref>, <xref rid="bvac185-B84" ref-type="bibr">84</xref>].</p><sec id="bvac185-s2.3.1"><title>Oral glucocorticoids</title><p>The daily requirement of a patient with AI to maintain basal, nonstressed body functions is approximately 4 to 5&#8197;mg prednisone equivalent per day. To stratify the risk of HPA axis suppression, GC intake may be divided into low dose (&lt;5&#8197;mg prednisone equivalent), medium dose (5-20&#8197;mg), and high dose (&gt;20&#8197;mg) per day. The duration of GC exposure can be considered as short-term (&lt;1 month), intermediate-duration (between 1-3 months), and long-term (&gt;3 months). However, these subclassifications have a role in perioperative management of patients if there is a plan to stop GCs before the procedure. Otherwise, most patients should receive a short course of GCs perioperatively based on the level of surgical stress and then return to their basal dose as they recover.</p><p>Low-dose GCs administered in the morning, for any duration of time, seem to have a low risk of causing clinically significant AI. In a study of 50 patients on long-term prednisone (mean duration approximately 4 years), those receiving &lt;5&#8197;mg/day showed a normal or near-normal response to the Cosyntropin stimulation test (CST) without AI-related events [<xref rid="bvac185-B85" ref-type="bibr">85</xref>]. Accordingly, we do not recommend additional workup in patients taking &lt;5&#8197;mg prednisone equivalent per day in the morning beyond the continuation of their glucocorticoids and monitoring them for any signs and symptoms of AI. However, it is also important to consider the cumulative effect of previous glucocorticoids in patients in whom the dose of GCs has been tapered to less than 5&#8197;mg prednisone equivalent per day at the time of their surgical evaluation. Such patients should receive a short course of parenteral GC therapy when unable to take their daily GC dose.</p><p>High-dose GCs taken for short-term frequently cause HPA axis suppression although rarely clinically significant AI. Carella et al reported that a short course of high dose of prednisone (40&#8197;mg 3 times per day for 3 days followed by a taper during the subsequent 4 days) resulted in transient HPA axis suppression [<xref rid="bvac185-B86" ref-type="bibr">86</xref>]. HPA axis recovery based on a CRH and CST was seen 1 week after treatment. Similarly, Spiegel et al showed that prednisone at doses of 40&#8197;mg/m<sup>2</sup> to 100&#8197;mg/m<sup>2</sup> daily for &lt;1 month could result in HPA axis suppression with recovery in &lt;1 week and no clinically significant AI events. In the authors&#8217; experience, it is common to see random and morning cortisol levels &lt;5&#8197;&#181;g/dL within a few days after a 6-day course of methylprednisolone (&#8220;Medrol pack&#8221;) or short courses of &#8220;pulse doses&#8221; of methylprednisolone (250-1000&#8197;mg). However, neither the literature review nor our observations have found clinically significant AI-related events in such patients. Therefore, the duration of therapy seems to have a greater impact than the dose on HPA axis suppression. Indeed, all historically reported adrenal crises have been in patients on chronic GC therapy. Therefore, we do not recommend any action outside of routine perioperative monitoring in patients who have been on GCs for &lt;4 weeks prior to surgery.</p><p>Patients taking 5&#8197;mg or more of prednisone equivalent per day for &gt;1 month may have variable degrees of HPA axis suppression [<xref rid="bvac185-B87" ref-type="bibr">87</xref>]. The risk of HPA axis suppression is higher in patients taking higher doses for a longer duration. Such patients should not stop GCs prior to surgery without further evaluation of the HPA axis. The majority of these patients can stay on their current dose of GC perioperatively and can be administered a short course of intravenous GC postoperatively until they resume their oral intake (see therapy section).</p><sec id="bvac185-s2.3.1.1"><title>Other variables that influence the risk of HPA axis suppression</title><p>The time of the day of GC administration can influence the risk of HPA axis suppression. In 8 healthy subjects who received 0.5&#8197;mg of dexamethasone at midnight for 2 consecutive nights, there was a more prolonged HPA axis suppression compared to those who received the same regimen at 8 <sc>Am</sc> or 4 <sc>Pm</sc> [<xref rid="bvac185-B88" ref-type="bibr">88</xref>]. The administration of multiple GC doses throughout the day carries a higher risk for HPA axis suppression than the same total daily dose taken once a day [<xref rid="bvac185-B87" ref-type="bibr">87</xref>, <xref rid="bvac185-B89" ref-type="bibr">89</xref>]. Myles et al in a crossover design compared cortisol levels after giving patients a single dose of prednisolone at 10 <sc>Am</sc> for 8 weeks vs the same total daily dose divided as half at 10 <sc>Am</sc> and the other half at 10 <sc>Pm</sc> for 8 weeks, returning to a single daily dose after [<xref rid="bvac185-B89" ref-type="bibr">89</xref>]. Cortisol levels were significantly lower in patients during the time the dose was split compared to when patients received a single daily dose of prednisolone. Alternate-day (morning) GC regimens are associated with a lower incidence of iatrogenic Cushing syndrome and HPA axis suppression [<xref rid="bvac185-B64" ref-type="bibr">64</xref>, <xref rid="bvac185-B90" ref-type="bibr">90</xref>].</p><p>There is a higher risk of AI-related clinical events if GCs are stopped closer to the date of surgical procedure, as the HPA axis needs time to recover [<xref rid="bvac185-B34" ref-type="bibr">34</xref>]. In patients with inflammatory bowel disease (IBD) taking up to 180&#8197;mg/day of prednisone for 2 to 23 months, the ones who stopped prednisone &gt;2 months prior to surgery had the lowest risk of developing AI-related hypotension [<xref rid="bvac185-B76" ref-type="bibr">76</xref>]. This retrospective study should be interpreted with caution since, when adjusted by disease severity, no differences in hypotension were observed.</p></sec></sec><sec id="bvac185-s2.3.2"><title>Nonoral glucocorticoid use</title><sec id="bvac185-s2.3.2.1"><title>Intra-articular and epidural injections</title><p>The risk of AI with intra-articular GCs remains largely unrecognized and likely underestimated [<xref rid="bvac185-B72" ref-type="bibr">72</xref>]. Both the absorption and the ability to suppress the HPA axis are proportional to the GC dose, half-life, solubility, vascularization of the synovium (increased during inflammation), number of joints injected, and frequency of injections [<xref rid="bvac185-B91" ref-type="bibr">91&#8211;93</xref>]. In a meta-analysis, the intra-articular and the oral route carried the highest risk for HPA axis suppression [<xref rid="bvac185-B81" ref-type="bibr">81</xref>]. In a small randomized controlled study that used a single fixed dose of 80&#8197;mg of methylprednisolone knee injection vs placebo, 25% of the patients receiving GC developed HPA axis suppression between week 2 and 4 after injection, and then returned to baseline [<xref rid="bvac185-B94" ref-type="bibr">94</xref>]. When multiple joints are simultaneously injected, HPA axis suppression takes longer to recover. Habib et al reported that injecting 80&#8197;mg of methylprednisolone acetate in both knees simultaneously resulted in HPA axis suppression in 60% of the patients by week 1, 30% to 35% between week 2 and 4, and 10% of patients at week 8 [<xref rid="bvac185-B95" ref-type="bibr">95</xref>]. Epidural GC injections can also result in rapid and prolonged HPA axis suppression. A single dose of triamcinolone resulted in suppression of the HPA axis within 1 week, slowly returning to baseline in about 4 to 12 weeks [<xref rid="bvac185-B96" ref-type="bibr">96</xref>]. We receive a substantial number of referrals for AI of unknown etiology where previous GC injections were not elicited from the history. Until better quality data is available, we recommend evaluating the HPA axis in patients who have received 3 or more GC injections within 6 months before surgery [<xref rid="bvac185-B97" ref-type="bibr">97</xref>].</p></sec><sec id="bvac185-s2.3.2.2"><title>Inhaled and intranasal</title><p>Inhaled GCs are absorbed systemically by the pulmonary vasculature with a smaller fraction swallowed and absorbed by the gastrointestinal tract [<xref rid="bvac185-B72" ref-type="bibr">72</xref>]. In a systematic review in patients with asthma using only inhaled GCs, higher risk of HPA axis suppression was seen with high doses of fluticasone equivalent (&gt;1000&#8197;mcg/day), compared to medium (200-1000&#8197;mcg/day) and low doses (&lt;200&#8197;mcg/day), resulting in AI in 18.5%, 5.4% and 1.5% of patients, respectively. When analyzed by the duration of treatment, long-term use (&gt;1 year) had a higher prevalence of AI compared to medium (1 month to 1 year) and short term (&lt;1 month); duration of treatment was associated with abnormal HPA axis in 20.3%, 9.0%, and 1.3% of patients, respectively [<xref rid="bvac185-B81" ref-type="bibr">81</xref>]. Another meta-analysis showed that the risk of basal cortisol suppression was higher with fluticasone compared to other inhaled steroids at the same equivalent dose [<xref rid="bvac185-B98" ref-type="bibr">98</xref>]. The literature on AI from intranasal GCs is scarce. Intranasal fluticasone preparations in the United States are sold in quantities of 27.5&#8197;mcg and 50&#8197;mcg per spray. However, fluticasone nasal sprays purchased outside the United States may have higher strengths; authors have treated a patient who purchased fluticasone abroad at a strength of 250&#8197;mcg per spray resulting in GC-induced AI.</p></sec><sec id="bvac185-s2.3.2.3"><title>Topical glucocorticoids</title><p>Topical GCs are classified based on potency into 7 classes and 3 subgroups: ultra-high (Class 1-3), moderate (Class 4-5), and low (Class 6-7) potency corticosteroids. Topical GCs can be absorbed systemically through the skin depending on the surface area of application, location applied, and skin thickness and integrity of the skin (ie, ulcerated, injured, or inflamed skin results in greater absorption) [<xref rid="bvac185-B72" ref-type="bibr">72</xref>]. Suppression of the HPA axis and AI can occur with the most potent topical GCs, clobetasol propionate 0.05% (Class 1), and betamethasone dipropionate 0.05% (Class 2). Iatrogenic Cushing syndrome accompanied by HPA axis suppression has been reported in adults with doses of approximately 33 to 100&#8197;g/week of clobetasol propionate and 49 to 80&#8197;mg/week of beclomethasone dipropionate [<xref rid="bvac185-B99" ref-type="bibr">99&#8211;101</xref>]. A fingertip of GC in a 5&#8197;mm nozzle tube is about 0.5&#8197;g (slightly lower in women) [<xref rid="bvac185-B102" ref-type="bibr">102</xref>]. HPA axis suppression may appear within days of the use of high potency topical GC and the duration of suppression is variable from weeks to months [<xref rid="bvac185-B99" ref-type="bibr">99&#8211;101</xref>]. A 2002 literature review identified 1 fatality due AI in a child on whom large amounts of topical betamethasone was applied for generalized psoriasis [<xref rid="bvac185-B103" ref-type="bibr">103</xref>]. Therefore, patients using potent topical GCs for prolonged periods of time or in combination with systemic GCs need to be cautious about the development of AI.</p></sec><sec id="bvac185-s2.3.2.4"><title>Other routes</title><p>The ophthalmic and rectal routes of steroid application have been associated with HPA axis suppression in small studies or case reports. Ophthalmic solutions, when used excessively and for prolonged periods, can be systemically absorbed resulting in iatrogenic Cushing syndrome and HPA axis suppression [<xref rid="bvac185-B104" ref-type="bibr">104</xref>]. Rectal GCs (enemas) have been associated with systemic absorption and HPA axis suppression particularly when the rectal mucosa is injured, inflamed, or ulcerated [<xref rid="bvac185-B105" ref-type="bibr">105</xref>].</p></sec></sec></sec><sec id="bvac185-s2.4"><title>Special Situations</title><p>Many GCs are metabolized via cytochrome P450 3A4 (CYP3A4). Therefore, inhibition of this enzyme results in risk of higher GC levels and HPA axis suppression. Multiple medications are known to inhibit CYP3A4; for example, ritonavir, a protease inhibitor, has a known interaction with inhaled fluticasone [<xref rid="bvac185-B92" ref-type="bibr">92</xref>, <xref rid="bvac185-B106" ref-type="bibr">106</xref>, <xref rid="bvac185-B107" ref-type="bibr">107</xref>]. When taken concomitantly with ritonavir, fluticasone propionate at doses as low as 500&#8197;ug/day for 2 months can result in iatrogenic Cushing syndrome [<xref rid="bvac185-B108" ref-type="bibr">108</xref>]. Cobicistat, an HIV drug enhancer which also inhibits CYP3A4 when used with ritonavir, can make this interaction more severe [<xref rid="bvac185-B109" ref-type="bibr">109</xref>]. Beclomethasone dipropionate is metabolized to a lesser degree by CYP3A4 and therefore could be an alternative to fluticasone when a combination with CYP3A4 inhibitors is required. Conversely, when CYP3A4 inducers are used, GCs metabolism increases, which may result in increased risk of perioperative AI in patients on a fixed GC dose. Some examples of CYP3A4 inducers include antiepileptic drugs, rifampin, and mitotane [<xref rid="bvac185-B92" ref-type="bibr">92</xref>]. A list of drugs affecting the HPA axis is included in <xref rid="bvac185-T3" ref-type="table">Table 3</xref> [<xref rid="bvac185-B92" ref-type="bibr">92</xref>, <xref rid="bvac185-B110" ref-type="bibr">110</xref>, <xref rid="bvac185-B111" ref-type="bibr">111</xref>].</p><table-wrap position="float" id="bvac185-T3" orientation="portrait"><label>Table 3.</label><caption><p>
<bold>Common drugs affecting the hypothalamic-pituitary adrenal axis [</bold>
<xref rid="bvac185-B92" ref-type="bibr">92</xref>, <xref rid="bvac185-B97" ref-type="bibr">97</xref>, <xref rid="bvac185-B110" ref-type="bibr">110</xref>, <xref rid="bvac185-B111" ref-type="bibr">111</xref><bold>]</bold></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="center" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Drugs Affecting CRH and ACTH Synthesis or Secretion</th></tr></thead><tbody><tr><td colspan="2" rowspan="1">&#8195;Opioids (morphine, oxycodone, fentanyl, tramadol, methadone, heroin)<break/>Benzodiazepines (midazolam, oxazepam, alprazolam, diazepam)<break/>Megestrol Acetate<break/>&#8195;Medroxyprogesterone</td></tr><tr><td colspan="2" rowspan="1">
<bold>Drugs Affecting Cortisol Synthesis</bold>
</td></tr><tr><td colspan="2" rowspan="1">&#8195;Azoles (Ketoconazole/Levoketoconazole, Posaconazole, fluconazole)<break/>Etomidate<break/>&#8195;Metyrapone, Aminoglutethimide<break/>&#8195;Trilostane</td></tr><tr><td colspan="2" rowspan="1">
<bold>Drugs Affecting Cortisol Action</bold>
</td></tr><tr><td colspan="2" rowspan="1">&#8195;Mifepristone</td></tr><tr><td colspan="2" rowspan="1">
<bold>Drugs Affecting Cortisol Metabolism</bold>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Cytochrome P450 3A4 Inhibitors<break/>(Decrease Cortisol Metabolism)</td><td rowspan="1" colspan="1">Cytochrome P450 3A4 Inducers<break/>(Increase Cortisol Metabolism)</td></tr><tr><td rowspan="1" colspan="1">Protease inhibitors (darunavir, indinavir, lopinavir, nelfinavir, telaprevir, ritonavir)</td><td rowspan="1" colspan="1">Antiepileptic drugs (phenytoin, fosphenytoin, phenobarbital, primidone)</td></tr><tr><td rowspan="1" colspan="1">Cobicistat, Azoles (itraconazole, voriconazole), clarithromycin, Grapefruit juice, mifepristone</td><td rowspan="1" colspan="1">Carbamazepine, rifampin, and mitotane</td></tr><tr><td rowspan="1" colspan="1">Calcium channel blockers (verapamil, diltiazem), amiodarone, cimetidine, conivaptan, erythromycin, and imatinib<italic toggle="yes"><sup><xref rid="bvac185-tblfn2" ref-type="table-fn">b</xref></sup></italic></td><td rowspan="1" colspan="1">Nafcillin, rifabutin, bosentan, dorafenib, efavirenz, rifabutin, St John's wort<italic toggle="yes"><sup><xref rid="bvac185-tblfn1" ref-type="table-fn">a</xref></sup></italic></td></tr></tbody></table><table-wrap-foot><fn id="bvac185-tblfn1"><label>
a
</label><p>Less potent inducers.</p></fn><fn id="bvac185-tblfn2"><label>
b
</label><p>Less potent inhibitors.</p></fn></table-wrap-foot></table-wrap><p>Opioids such as morphine, oxycodone, fentanyl, tramadol, methadone, and heroin have been increasingly recognized as cause of GC-induced AI [<xref rid="bvac185-B112" ref-type="bibr">112</xref>]. Li et al reported a prevalence of about 9% of AI in chronic opioid users (mean duration of 60 months) leading them to suggest that adrenal function should be monitored in patients taking &gt; 20&#8197;mg of morphine equivalents per day [<xref rid="bvac185-B113" ref-type="bibr">113</xref>]. Benzodiazepines such as midazolam, oxazepam, alprazolam, and diazepam can also affect the HPA axis at the hypothalamic level [<xref rid="bvac185-B114" ref-type="bibr">114&#8211;116</xref>]. Other drugs such as megestrol acetate and medroxyprogesterone acetate have GC activity with potential for HPA axis suppression [<xref rid="bvac185-B92" ref-type="bibr">92</xref>]. In summary, careful review of the preoperative medications aimed at identifying drugs causing HPA axis impairment is critical. Recently, in the United Kingdom, a National Patient Safety Alert was issued stressing the importance of patients on chronic GCs to carry an emergency card to raise the awareness of the surgical team for appropriate perioperative GC management [<xref rid="bvac185-B117" ref-type="bibr">117</xref>].</p></sec></sec><sec id="bvac185-s3"><title>Evaluation of Adrenal Function in Patients Using Glucocorticoids</title><p>Patients should undergo HPA testing if there is a plan to stop GC before surgery (see therapy section). Morning and random (during stress) serum cortisol levels and the CST are the most commonly used tests for the evaluation of the HPA axis. Despite some studies pointing toward suboptimal sensitivity of the CST (high false negative), and even though the idea of assessing the entire HPA axis (using insulin tolerance or Metyrapone test) vs the adrenal response to exogenous ACTH analog is attractive, the authors are not aware of any reports of patients who passed the CST and suffered cardiovascular collapse perioperatively [<xref rid="bvac185-B118" ref-type="bibr">118&#8211;122</xref>]. The authors have taken care of a large number of patients with pituitary disorders who underwent surgery without GC coverage based on passing the CST. However, the CST may be unreliable in the first few weeks following an acute hypothalamic or pituitary event where the adrenal gland has not undergone enough atrophy [<xref rid="bvac185-B122" ref-type="bibr">122&#8211;124</xref>].</p><p>The laboratory evaluation of AI usually starts with obtaining a morning (7 <sc>Am</sc>-9 <sc>Am</sc>) serum cortisol measurement. Cortisol &lt;3&#8197;&#181;g/dL is diagnostic of AI; measuring ACTH levels will distinguish between primary and GC-induced AI [<xref rid="bvac185-B125" ref-type="bibr">125</xref>]. If morning cortisol levels are in the indeterminate range (3-10&#8197;&#181;g/dL), a CST may be performed [<xref rid="bvac185-B126" ref-type="bibr">126</xref>]. A stimulated cortisol value of &gt;14 to 15&#8197;&#181;g/dL at 30&#8197;minutes after 250&#8197;ug of IV or intramuscular Cosyntropin excludes AI [<xref rid="bvac185-B127" ref-type="bibr">127&#8211;129</xref>]. These cutoff values are suggested based on newer cortisol assays that use monoclonal antibodies and liquid chromatography with tandem mass spectrometry that result in about 20% to 0% lower cortisol levels compared to &gt;18&#8197;&#181;g/dL using polyclonal immunoassays [<xref rid="bvac185-B127" ref-type="bibr">127&#8211;130</xref>]. Dehydroepiandrosterone sulfate (DHEA-S) may be used to further assess the HPA axis in patients with indeterminate serum cortisol levels [<xref rid="bvac185-B131" ref-type="bibr">131</xref>]. A minimum DHEA-S level of 54&#8197;&#181;g/dL rather than the lower limit of the normal range for the age has been suggested. One caveat is that any GC exposure in the past may result in long-term low DHEAS levels despite normal cortisol reserve.</p></sec><sec id="bvac185-s4"><title>Perioperative Glucocorticoid Management</title><sec id="bvac185-s4.1"><title>Studies Evaluating the Effects of Supplemental Perioperative Glucocorticoids</title><p>Studies over the past several decades addressing the use of supplemental perioperative GCs in those on chronic GC therapy have major limitations. This has resulted in significant challenges to standardize clinical practice. As observed by Lamore et al, low-risk patients within the same institution often received hydrocortisone ranging between 50 and &gt;200&#8197;mg/day for similar surgical risk, demonstrating a lack of agreement among clinicians [<xref rid="bvac185-B132" ref-type="bibr">132</xref>].</p><p>The question of how much cortisol is needed to prevent adrenal crisis is still unanswered. Based on the 3 randomized controlled trials (RCTs) [<xref rid="bvac185-B133" ref-type="bibr">133&#8211;135</xref>], at least 6 cohort [<xref rid="bvac185-B118" ref-type="bibr">118</xref>, <xref rid="bvac185-B136" ref-type="bibr">136&#8211;140</xref>], and 1 retrospective studies [<xref rid="bvac185-B141" ref-type="bibr">141</xref>], in most cases continuing the daily preoperative GC regimen seems to be sufficient. The 3 RCTs had small sample sizes (between 17-92) and limitations, reflecting the need for additional studies in the field. Udelsman et al showed that in adrenalectomized primates who underwent open cholecystectomy, physiological GC replacement doses resulted in similar outcomes when compared to 10-fold supraphysiological doses [<xref rid="bvac185-B142" ref-type="bibr">142</xref>]. In contrast, when a subphysiological dose (1/10 of the normal cortisol production rate) was given perioperatively, more hemodynamic instability with a higher mortality rate was observed [<xref rid="bvac185-B142" ref-type="bibr">142</xref>]. In <xref rid="bvac185-T4" ref-type="table">Table 4</xref> we summarize the relevant clinical studies that support the notion that, in most cases, the current practice of perioperative GC administration is excessive and potentially harmful.</p><table-wrap position="float" id="bvac185-T4" orientation="portrait"><label>Table 4.</label><caption><p>Studies addressing supplemental perioperative glucocorticoid treatment</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Source</th><th align="left" rowspan="1" colspan="1">Type of Study</th><th align="left" rowspan="1" colspan="1">Population</th><th align="left" rowspan="1" colspan="1">Perioperative<break/>Glucocorticoid Regimen</th><th align="left" rowspan="1" colspan="1">Total Dose per Day</th><th align="left" rowspan="1" colspan="1">Duration of the Protocol</th><th align="left" rowspan="1" colspan="1">Type of Surgery</th><th align="left" rowspan="1" colspan="1">Outcome</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Solem<break/>1962 [<xref rid="bvac185-B136" ref-type="bibr">136</xref>]</td><td rowspan="1" colspan="1">Prospective</td><td rowspan="1" colspan="1">Heterogeneous<break/>(n = 78)</td><td rowspan="1" colspan="1">Group 1: A 7-day cortisone regimen for those under chronic glucocorticoid at the time of surgery<break/>vs<break/>Group 2: As needed therapy for those who stopped glucocorticoids &gt; 4 weeks pre-op</td><td rowspan="1" colspan="1">100&#8197;mg 1 day pre-op<break/>300-400&#8197;mg day 1<break/>200&#8197;mg day 2<break/>150&#8197;mg days 3-4<break/>100&#8197;mg days 5-6<break/>Baseline dose day 7</td><td rowspan="1" colspan="1">7 days</td><td rowspan="1" colspan="1">Various<break/>Mostly major stress</td><td rowspan="1" colspan="1">No AI in either group</td></tr><tr><td rowspan="1" colspan="1">Lloyd<break/>1981 [<xref rid="bvac185-B137" ref-type="bibr">137</xref>]</td><td rowspan="1" colspan="1">Prospective</td><td rowspan="1" colspan="1">RA<break/>(n = 61)</td><td rowspan="1" colspan="1">Group 1: Hydrocortisone once,<break/>then only if post-op hypotension vs<break/>Group 2: PRN hydrocortisone<break/>Patients in both groups were on their chronic glucocorticoid regimen</td><td rowspan="1" colspan="1">100&#8197;mg day 1</td><td rowspan="1" colspan="1">1 day</td><td rowspan="1" colspan="1">Various<break/>orthopedic procedures</td><td rowspan="1" colspan="1">PRN regimen was favored</td></tr><tr><td rowspan="1" colspan="1">Symbreg<break/>1981 [<xref rid="bvac185-B118" ref-type="bibr">118</xref>]</td><td rowspan="1" colspan="1">Prospective</td><td rowspan="1" colspan="1">Heterogeneous<break/>(n = 22)</td><td rowspan="1" colspan="1">Group 1: Controls not previously exposed to glucocorticoids<break/>Group 2: Hydrocortisone treatment if abnormal CST<break/>vs<break/>Group 3: Monitoring if normal CST<italic toggle="yes"><sup>b</sup></italic></td><td rowspan="1" colspan="1">125&#8197;mg day 1</td><td rowspan="1" colspan="1">1 day</td><td rowspan="1" colspan="1">Various<break/>Mostly major stress</td><td rowspan="1" colspan="1">No AI in either group<italic toggle="yes"><sup><xref rid="bvac185-tblfn5" ref-type="table-fn">a</xref></sup></italic></td></tr><tr><td rowspan="1" colspan="1">Shapiro<break/>1990 [<xref rid="bvac185-B139" ref-type="bibr">139</xref>]</td><td rowspan="1" colspan="1">Prospective</td><td rowspan="1" colspan="1">Renal transplant<break/>(n = 13)</td><td rowspan="1" colspan="1">Group 1: Continued their daily dose of prednisone (no supplemental glucocorticoids were given)</td><td rowspan="1" colspan="1">5-20&#8197;mg</td><td rowspan="1" colspan="1">n/a</td><td rowspan="1" colspan="1">Allograft Nephrectomy</td><td rowspan="1" colspan="1">No AI with continuing daily dose of prednisone</td></tr><tr><td rowspan="1" colspan="1">Bromberg<break/>1991 [<xref rid="bvac185-B138" ref-type="bibr">138</xref>]</td><td rowspan="1" colspan="1">Prospective<break/>(Cohort)</td><td rowspan="1" colspan="1">Renal Transplant<break/>(n = 40)</td><td rowspan="1" colspan="1">Group 1: Same population Controls<break/>Group 2: Continue daily dose of prednisone (no supplemental glucocorticoids were given)</td><td rowspan="1" colspan="1">5-10 mg</td><td rowspan="1" colspan="1">n/a</td><td rowspan="1" colspan="1">Various surgical and non-surgical stress</td><td rowspan="1" colspan="1">No AI with continuing daily dose of prednisone</td></tr><tr><td rowspan="1" colspan="1">Friedman<break/>1995 [<xref rid="bvac185-B140" ref-type="bibr">140</xref>]</td><td rowspan="1" colspan="1">Prospective</td><td rowspan="1" colspan="1">RA, renal transplant<break/>(n = 28)</td><td rowspan="1" colspan="1">Group 1: Continued their daily dose of prednisone (no supplemental glucocorticoids were given)</td><td rowspan="1" colspan="1">1-20 mg</td><td rowspan="1" colspan="1">n/a</td><td rowspan="1" colspan="1">Major orthopedic surgeries</td><td rowspan="1" colspan="1">No AI with continuing daily dose of prednisone</td></tr><tr><td rowspan="1" colspan="1">Bromberg<break/>1995 [<xref rid="bvac185-B143" ref-type="bibr">143</xref>]</td><td rowspan="1" colspan="1">Prospective</td><td rowspan="1" colspan="1">Renal transplant<break/>(n = 52)</td><td rowspan="1" colspan="1">Group 1: Continued their daily dose of prednisone (no supplemental glucocorticoids were given)</td><td rowspan="1" colspan="1">5-15 mg</td><td rowspan="1" colspan="1">n/a</td><td rowspan="1" colspan="1">Various</td><td rowspan="1" colspan="1">No AI with continuing daily dose of prednisone</td></tr><tr><td rowspan="1" colspan="1">Glowniak<break/>1997 [<xref rid="bvac185-B133" ref-type="bibr">133</xref>]</td><td rowspan="1" colspan="1">Randomized controlled trial</td><td rowspan="1" colspan="1">Heterogeneous<break/>(n = 17)</td><td rowspan="1" colspan="1">Group 1: Daily dose + stress dose hydrocortisone<break/>vs<break/>Group 2: Daily dose + saline (placebo)</td><td rowspan="1" colspan="1">200&#8197;mg day 1<break/>100&#8197;mg day 2<break/>50&#8197;mg day 3</td><td rowspan="1" colspan="1">3 days</td><td rowspan="1" colspan="1">Various</td><td rowspan="1" colspan="1">No additional benefit from stress dose hydrocortisone</td></tr><tr><td rowspan="1" colspan="1">Thomason<break/>1999 [<xref rid="bvac185-B135" ref-type="bibr">135</xref>]</td><td rowspan="1" colspan="1">Randomized controlled trial<break/>Crossover</td><td rowspan="1" colspan="1">Organ<break/>transplant<break/>(n = 20)</td><td rowspan="1" colspan="1">Group 1: Daily dose + single stress dose hydrocortisone<break/>vs<break/>Group 2: Daily dose + saline<break/>(placebo)</td><td rowspan="1" colspan="1">100&#8197;mg</td><td rowspan="1" colspan="1">1 day</td><td rowspan="1" colspan="1">Gingival surgeries<break/>Minor stress</td><td rowspan="1" colspan="1">No additional benefit from stress dose hydrocortisone<break/>No AI in either group</td></tr><tr><td rowspan="1" colspan="1">Mathis<break/>2004 [<xref rid="bvac185-B141" ref-type="bibr">141</xref>]</td><td rowspan="1" colspan="1">Retrospective</td><td rowspan="1" colspan="1">Renal Transplant<break/>(n = 58)</td><td rowspan="1" colspan="1">Group 1: Stress dose glucocorticoids<break/>vs<break/>Group 2: No stress dose<italic toggle="yes"><sup>b</sup></italic></td><td rowspan="1" colspan="1">n/a</td><td rowspan="1" colspan="1">n/a</td><td rowspan="1" colspan="1">Lymphocele drainage</td><td rowspan="1" colspan="1">No additional benefit from stress dose glucocorticoids and more hyperglycemia was reported</td></tr><tr><td rowspan="1" colspan="1">Zaghiyan<break/>2011 [<xref rid="bvac185-B144" ref-type="bibr">144</xref>]</td><td rowspan="1" colspan="1">Retrospective</td><td rowspan="1" colspan="1">IBD<break/>(n = 49)</td><td rowspan="1" colspan="1">Group 1: Stress dose glucocorticoids<break/>vs<break/>Group 2: No stress dose</td><td rowspan="1" colspan="1">100&#8197;mg (incision)<break/>300&#8197;mg day 1<break/>Taper to prednisone 20&#8197;mg per day</td><td rowspan="1" colspan="1">4 days</td><td rowspan="1" colspan="1">Major abdominal surgeries</td><td rowspan="1" colspan="1">No additional benefit from stress dose glucocorticoids<break/>No AI in either group</td></tr><tr><td rowspan="1" colspan="1">Zaghiyan<break/>2012 [<xref rid="bvac185-B145" ref-type="bibr">145</xref>]</td><td rowspan="1" colspan="1">Prospective</td><td rowspan="1" colspan="1">IBD<break/>(n = 32)</td><td rowspan="1" colspan="1">Group 1: Patient not currently on glucocorticoid (but previously exposed during the past 12 months) received no treatment perioperatively<break/>vs<break/>Group 2: Patients currently on glucocorticoids receiving low-dose supplemental glucocorticoids perioperatively</td><td rowspan="1" colspan="1">One-third of pre-op dose (incision)<break/>One-third of the dose Q8hrs day of surgery<break/>One-fourth Q8hr day 1<break/>One-sixth Q8hr day 2<break/>One-fourth Q12hr day 3<break/>Prednisone equivalent day 4</td><td rowspan="1" colspan="1">4 days</td><td rowspan="1" colspan="1">Major abdominal surgeries</td><td rowspan="1" colspan="1">No AI in either group<break/>Low-dose supplemental glucocorticoid regimens seem safe</td></tr><tr><td rowspan="1" colspan="1">Zaghiyan<break/>2012 [<xref rid="bvac185-B146" ref-type="bibr">146</xref>]</td><td rowspan="1" colspan="1">Retrospective</td><td rowspan="1" colspan="1">IBD<break/>(n = 97)</td><td rowspan="1" colspan="1">Group 1: High (stress) dose glucocorticoids<break/>vs<break/>Group 2: Low-dose supplemental glucocorticoid (see [<xref rid="bvac185-B145" ref-type="bibr">145</xref>])</td><td rowspan="1" colspan="1">100&#8197;mg (Incision)<break/>300&#8197;mg day 1<break/>Taper to prednisone</td><td rowspan="1" colspan="1">4 days</td><td rowspan="1" colspan="1">Major abdominal surgeries</td><td rowspan="1" colspan="1">No AI in either group<break/>No additional benefit from high-dose stress glucocorticoids</td></tr><tr><td rowspan="1" colspan="1">Ayatac<break/>2013 [<xref rid="bvac185-B147" ref-type="bibr">147</xref>]</td><td rowspan="1" colspan="1">Retrospective</td><td rowspan="1" colspan="1">IBD<break/>(n = 235)</td><td rowspan="1" colspan="1">Group 1: Daily dose + Stress dose glucocorticoids<break/>vs<break/>Group 2: Daily dose (unless off glucocorticoids preoperatively) + no stress dose</td><td rowspan="1" colspan="1">100&#8197;mg (operating room)<break/>300&#8197;mg day 1<break/>Then taper</td><td rowspan="1" colspan="1">n/a</td><td rowspan="1" colspan="1">Major abdominal surgeries</td><td rowspan="1" colspan="1">One case of AI in group 1.<break/>No additional benefit or harm was seen from stress dose glucocorticoids</td></tr><tr><td rowspan="1" colspan="1">Zaghiyan<break/>2014 [<xref rid="bvac185-B134" ref-type="bibr">134</xref>]</td><td rowspan="1" colspan="1">Single blinded randomized controlled trial</td><td rowspan="1" colspan="1">IBD<break/>(n = 92)</td><td rowspan="1" colspan="1">Group 1: Stress dose hydrocortisone<break/>vs<break/>Group 2: Hydrocortisone equivalent to oral daily dose</td><td rowspan="1" colspan="1">100&#8197;mg (incision)<break/>300&#8197;mg day 1<break/>225&#8197;mg day 2<break/>150&#8197;mg day 3<break/>100&#8197;mg day 4<break/>20&#8197;mg Prednisone</td><td rowspan="1" colspan="1">5 days</td><td rowspan="1" colspan="1">Major abdominal surgeries</td><td rowspan="1" colspan="1">No additional benefit from stress dose glucocorticoids</td></tr></tbody></table><table-wrap-foot><fn id="bvac185-tblfn3"><p>Excluded studies where both chronic glucocorticoids and supplemental treatment were not provided [<xref rid="bvac185-B33" ref-type="bibr">33</xref>, <xref rid="bvac185-B148" ref-type="bibr">148</xref>].</p></fn><fn id="bvac185-tblfn4"><p>AI, adrenal insufficiency; CST, cosyntropin stimulation test; IBD, inflammatory bowel disease; n/a, not available; RA, rheumatoid arthritis.</p></fn><fn id="bvac185-tblfn5"><label>
a
</label><p>125&#8197;mg resulted in higher cortisol levels than nonexposed.</p></fn><fn id="bvac185-tblfn6"><p>
<italic toggle="yes">
<sup>b</sup>
</italic>Unclear if patients were receiving or stopped chronic glucocorticoids at the time of surgery.</p></fn></table-wrap-foot></table-wrap><p>The first RCT studied 17 patients on prednisone 5 to 60&#8197;mg/day for a duration of 2 months to 20 years [<xref rid="bvac185-B133" ref-type="bibr">133</xref>]. All patients had abnormal CST. These patients were kept on their daily dose of prednisone and randomized to saline injections vs stress doses of 200&#8197;mg of hydrocortisone with a gradual taper over 3 days. No adrenal crisis was observed in the group on the daily dose of GC and placebo [<xref rid="bvac185-B133" ref-type="bibr">133</xref>]. In the second RCT, 20 solid organ transplant patients receiving maintenance doses of prednisone (5-10&#8197;mg/day) were randomized to continue their chronic GC regimen vs additional 100&#8197;mg of hydrocortisone during gingival surgery under local anesthesia. No significant difference in hypotension or signs of AI was observed in either group [<xref rid="bvac185-B135" ref-type="bibr">135</xref>]. Lastly, a single blinded RCT included 92 patients with IBD undergoing major colorectal surgery who were randomized to receive either hydrocortisone 100&#8197;mg every 8&#8197;hours. followed by a taper, or IV hydrocortisone equivalent dose of the presurgical GC regimen [<xref rid="bvac185-B134" ref-type="bibr">134</xref>]. As with the previous RCTs, there was no evidence of hemodynamic benefit from supplemental stress dose GCs.</p><p>The retrospective and nonrandomized prospective studies support the RCTs&#8217; results. In kidney transplant patients on an average prednisone dose of 15.5&#8197;mg/day for &gt;84 days, adding stress dose GCs to their chronic GC regimen did not provide additional hemodynamic benefit during minor surgical procedures but increased the risk of hyperglycemia [<xref rid="bvac185-B141" ref-type="bibr">141</xref>]. In another study, 40 renal transplant patients on GCs for at least 3 months were admitted to the hospital for various reasons (sepsis, metabolic abnormalities, surgery). They continued their daily prednisone regimen of 5 to 10&#8197;mg/day without supplemental treatment. When comparing this group to the same population of patients with renal allograft admitted to the hospital for various reasons during the same period of time, there was no increased mortality, length of hospital stay, or adrenal crises [<xref rid="bvac185-B138" ref-type="bibr">138</xref>]. Other groups consistently demonstrated a lack of benefit of stress dose GCs in patients with IBD undergoing major abdominal surgery [<xref rid="bvac185-B76" ref-type="bibr">76</xref>, <xref rid="bvac185-B144" ref-type="bibr">144&#8211;147</xref>].</p><p>In general, the literature supports the concept that continuing the daily GC dose in patients suspected to have GC-induced AI is sufficient to prevent adrenal crises perioperatively. In fact, in the only 3 confirmed postoperative adrenal crisis-related deaths, chronic supraphysiological GC doses were stopped before surgery [<xref rid="bvac185-B8" ref-type="bibr">8</xref>]. Based on the level of surgical stress, parenteral GC treatment in patients who cannot tolerate oral intake is reasonable with a gradual return to daily GC dose once daily intake is resumed (<xref rid="bvac185-T5" ref-type="table">Table 5</xref>).</p><table-wrap position="float" id="bvac185-T5" orientation="portrait"><label>Table 5.</label><caption><p>Perioperative treatment regimens suggested for patient with glucocorticoid-induced AI</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Regimen</th><th align="left" rowspan="1" colspan="1">Degree of Surgical Stress</th><th align="left" rowspan="1" colspan="1">Glucocorticoid Regimen</th></tr></thead><tbody><tr><td rowspan="3" colspan="1">Patients currently on glucocorticoids</td><td rowspan="1" colspan="1">Garde I<break/>Minor</td><td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Continue daily dose of glucocorticoid</p></list-item><list-item><p>25&#8197;mg of IV hydrocortisone at induction if not able to tolerate PO</p></list-item><list-item><p>Resume oral daily preoperative glucocorticoid regimen</p></list-item></list>
</td></tr><tr><td rowspan="1" colspan="1">Grade II<break/>Moderate</td><td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Continue daily dose of glucocorticoid</p></list-item><list-item><p>25-50&#8197;mg of hydrocortisone IV at induction</p></list-item><list-item><p>15-25&#8197;mg hydrocortisone every 6&#8197;hours. until PO is tolerated and hemodynamically stable<italic toggle="yes"><sup><xref rid="bvac185-tblfn9" ref-type="table-fn">a</xref></sup></italic></p></list-item><list-item><p>Resume oral daily preoperative glucocorticoid regimen</p></list-item></list>
</td></tr><tr><td rowspan="1" colspan="1">Grade III<break/>Major</td><td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Continue daily dose of glucocorticoid</p></list-item><list-item><p>50&#8197;mg of hydrocortisone IV at induction</p></list-item><list-item><p>25&#8197;mg of hydrocortisone IV every 6&#8197;hours on day 1 and until hemodynamically stable, then 15&#8197;mg IV every 6&#8197;hours until PO is tolerated<italic toggle="yes"><sup><xref rid="bvac185-tblfn9" ref-type="table-fn">a</xref></sup></italic></p></list-item><list-item><p>Resume oral daily preoperative glucocorticoid regimen</p></list-item></list>
</td></tr><tr><td colspan="2" rowspan="1">Patients who stopped or plan to stop glucocorticoids before surgery</td><td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Assess HPA axis in patients with intermediate to high risk (see <xref rid="bvac185-T4" ref-type="table">Table 4</xref>)</p></list-item><list-item><p>The closer the date of discontinuing glucocorticoids before surgery, the higher the risk of AI</p></list-item><list-item><p>Treat based on the degree of surgical stress in those who have abnormal HPA axis</p></list-item></list>
</td></tr><tr><td colspan="2" rowspan="1">Adrenal crisis</td><td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>100&#8197;mg of hydrocortisone IV (IM if no IV access)</p></list-item><list-item><p>50&#8197;mg every 6&#8197;hours until hemodynamically stable and then taper<italic toggle="yes"><sup><xref rid="bvac185-tblfn9" ref-type="table-fn">a</xref></sup></italic></p></list-item><list-item><p>Taper depending on clinical response-intravenous fluids (normal saline), dextrose 5% if hypoglycemia</p></list-item></list>
</td></tr></tbody></table><table-wrap-foot><fn id="bvac185-tblfn7"><p>These recommendations include the authors&#8217; personalized approach to perioperative management in patients with glucocorticoid-induced AI.</p></fn><fn id="bvac185-tblfn8"><p>AI, adrenal insufficiency; HPA, hypothalamic-pituitary-adrenal; IM, intramuscular; IV, intravenous; PO, by mouth.</p></fn><fn id="bvac185-tblfn9"><label>
a
</label><p>Some experts favor continuous glucocorticoid infusion.</p></fn></table-wrap-foot></table-wrap></sec><sec id="bvac185-s4.2"><title>Glucocorticoid &#8220;Coverage&#8221;</title><p>There have been a large number of supplemental perioperative GC regimens recommended over the past decades [<xref rid="bvac185-B6" ref-type="bibr">6</xref>, <xref rid="bvac185-B8" ref-type="bibr">8</xref>, <xref rid="bvac185-B11" ref-type="bibr">11</xref>, <xref rid="bvac185-B17" ref-type="bibr">17</xref>, <xref rid="bvac185-B66" ref-type="bibr">66&#8211;156</xref>]. Some of these recommendations were based on estimated cortisol production rates during stress and others empirically based. Simultaneously, experts in the field have consistently voiced their concerns about the excess amount of GC coverage, which may be harmful (<xref rid="bvac185-T6" ref-type="table">Table 6</xref>). Awareness of the lack of evidence to support the use of high-dose perioperative GCs and the associated risks has resulted in a trend to recommend lower doses and shorter duration of these protocols [<xref rid="bvac185-B12" ref-type="bibr">12&#8211;14</xref>]&#8212;from &gt;300&#8197;mg of hydrocortisone [<xref rid="bvac185-B118" ref-type="bibr">118</xref>] to about 100 to 200&#8197;mg/day [<xref rid="bvac185-B11" ref-type="bibr">11</xref>, <xref rid="bvac185-B66" ref-type="bibr">66</xref>, <xref rid="bvac185-B70" ref-type="bibr">70</xref>, <xref rid="bvac185-B150" ref-type="bibr">150</xref>, <xref rid="bvac185-B156" ref-type="bibr">156</xref>] and shorter tapers over &lt;7 days&#8212;without increased mortality.</p><table-wrap position="float" id="bvac185-T6" orientation="portrait"><label>Table 6.</label><caption><p>Review articles that commented on perioperative glucocorticoid treatment regimen</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Source</th><th align="left" rowspan="1" colspan="1">Year</th><th align="left" rowspan="1" colspan="1">Comments from the Authors</th><th align="left" rowspan="1" colspan="1">Conclusions on Treatment</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Kehlet [<xref rid="bvac185-B151" ref-type="bibr">151</xref>]</td><td rowspan="1" colspan="1">1975</td><td rowspan="1" colspan="1">&#8220;Glucocorticoid should only be given in a necessary and adequate dose&#8221; to avoid side effects</td><td rowspan="1" colspan="1">Most regimens are founded on empirical basis</td></tr><tr><td rowspan="1" colspan="1">Salem [<xref rid="bvac185-B8" ref-type="bibr">8</xref>]</td><td rowspan="1" colspan="1">1994</td><td rowspan="1" colspan="1">The risk should be individualized based on the glucocorticoid preoperative dose, duration, and type of surgery</td><td rowspan="1" colspan="1">We are giving too much glucocorticoids</td></tr><tr><td rowspan="1" colspan="1">De Lange [<xref rid="bvac185-B157" ref-type="bibr">157</xref>]</td><td rowspan="1" colspan="1">2008</td><td rowspan="1" colspan="1">There is no evidence to support excessive dosing (&gt;200&#8197;mg hydrocortisone equivalent/day) or extensive duration in uncomplicated cases</td><td rowspan="1" colspan="1">We are giving too much glucocorticoids</td></tr><tr><td rowspan="1" colspan="1">Marik [<xref rid="bvac185-B158" ref-type="bibr">158</xref>]</td><td rowspan="1" colspan="1">2008</td><td rowspan="1" colspan="1">&#8220;Stress doses are not routinely required as long as the patient continues their usual daily dose of glucocorticoids&#8221;</td><td rowspan="1" colspan="1">We are giving too much glucocorticoids</td></tr><tr><td rowspan="1" colspan="1">Fleager [<xref rid="bvac185-B155" ref-type="bibr">155</xref>]</td><td rowspan="1" colspan="1">2010</td><td rowspan="1" colspan="1">&#8220;There are no evidence-based treatment guidelines that provide firm recommendations for the administration of perioperative steroids&#8221;</td><td rowspan="1" colspan="1">No evidence for current practice</td></tr><tr><td rowspan="1" colspan="1">Kelly [<xref rid="bvac185-B159" ref-type="bibr">159</xref>]</td><td rowspan="1" colspan="1">2013</td><td rowspan="1" colspan="1">Based on the existing evidence, patients on long-term glucocorticoids do not require the once-standard high doses; just continue their maintenance doses perioperatively. Treat refractory hypotension with rescue doses of steroids</td><td rowspan="1" colspan="1">We are giving too much glucocorticoids</td></tr><tr><td rowspan="1" colspan="1">Hicks [<xref rid="bvac185-B160" ref-type="bibr">160</xref>]</td><td rowspan="1" colspan="1">2015</td><td rowspan="1" colspan="1">&#8220;Current prescribing practices are highly variable, likely because of a lack of randomized controlled data and a wide range of preoperative treatment regimens&#8221;</td><td rowspan="1" colspan="1">&#8220;Recent data suggest that additional corticosteroid supplementation in the perioperative period may be unnecessary and may serve only to increase the risk of poor wound healing and infectious&#8221;</td></tr><tr><td rowspan="1" colspan="1">MacKenzie [<xref rid="bvac185-B161" ref-type="bibr">161</xref>]</td><td rowspan="1" colspan="1">2016</td><td rowspan="1" colspan="1">&#8220;Despite little evidence for this practice (supraphysiological supplemental perioperative glucocorticoids), few have challenged this treatment paradigm&#8221;</td><td rowspan="1" colspan="1">&#8220;With few exceptions, the use of supraphysiologic glucocorticoid therapy for adults with presumed adrenal insufficiency due to exogenous glucocorticoid use should be regarded as unnecessary&#8221;</td></tr><tr><td rowspan="1" colspan="1">Liu [<xref rid="bvac185-B156" ref-type="bibr">156</xref>]</td><td rowspan="1" colspan="1">2017</td><td rowspan="1" colspan="1">&#8220;Recommendations in major textbooks are confusing, inconsistent, and lacking in class A or B evidence&#8221;</td><td rowspan="1" colspan="1">There is no universal agreement regarding dose, duration, or regimen of supplemental glucocorticoid</td></tr><tr><td rowspan="1" colspan="1">Groleau [<xref rid="bvac185-B9" ref-type="bibr">9</xref>]</td><td rowspan="1" colspan="1">2018</td><td rowspan="1" colspan="1">&#8220;It is not possible to conclude that perioperative administration of corticosteroids, compared to placebo, reduced the incidence of adrenal insufficiency&#8221;</td><td rowspan="1" colspan="1">Providing the daily maintenance dose without supplemental glucocorticoids may be sufficient</td></tr><tr><td rowspan="1" colspan="1">Khazen [<xref rid="bvac185-B162" ref-type="bibr">162</xref>]</td><td rowspan="1" colspan="1">2018</td><td rowspan="1" colspan="1">&#8220;We found no evidence to support the use of supraphysiologic dose of glucocorticoid therapy provided the patient receive their usual dose of glucocorticoid preoperatively&#8221;</td><td rowspan="1" colspan="1">&#8220;A well-designed, large multicenter RCT is warranted&#8221;</td></tr><tr><td rowspan="1" colspan="1">Chilkoti [<xref rid="bvac185-B66" ref-type="bibr">66</xref>]</td><td rowspan="1" colspan="1">2019</td><td rowspan="1" colspan="1">&#8220;There are no dogmatic guidelines regarding perioperative &#8220;stress dose&#8221; of steroids in patients on chronic steroid therapy; however, there is enough evidence that patients on long-term exogenous steroid therapy do not require the conventional high-dose perioperative corticosteroid, instead must be kept on their baseline maintenance dose&#8221;</td><td rowspan="1" colspan="1">We are giving too much glucocorticoids</td></tr><tr><td rowspan="1" colspan="1">Manou-Stathopoulou [<xref rid="bvac185-B163" ref-type="bibr">163</xref>]</td><td rowspan="1" colspan="1">2019</td><td rowspan="1" colspan="1">&#8220;Clinical trials exploring glucocorticoid supplementation have provided conflicting data, reflecting the lack of understanding of the cortisol biology during the perioperative period&#8221;</td><td rowspan="1" colspan="1">More personalized targeted therapies are needed</td></tr><tr><td rowspan="1" colspan="1">Seo [<xref rid="bvac185-B11" ref-type="bibr">11</xref>]</td><td rowspan="1" colspan="1">2021</td><td rowspan="1" colspan="1">Many clinical trials have low level of evidence, lack of power, without clear criteria for AI that results in high variation in the recommendations</td><td rowspan="1" colspan="1">No evidence for current practice</td></tr><tr><td rowspan="1" colspan="1">Laugesen [<xref rid="bvac185-B10" ref-type="bibr">10</xref>]</td><td rowspan="1" colspan="1">2021</td><td rowspan="1" colspan="1">&#8220;Current evidence indicates substantial variation regarding risk and course of glucocorticoid-induced adrenal insufficiency &#8230; more research is needed to refine the diagnosis and to support evidence-based clinical decision-making&#8221;</td><td rowspan="1" colspan="1">No evidence for current practice</td></tr></tbody></table><table-wrap-foot><fn id="bvac185-tblfn10"><p>Many review articles discuss the topic and make recommendations without specific comments about the current practice.</p></fn><fn id="bvac185-tblfn11"><p>AI, adrenal insufficiency; RCT, randomized controlled trial.</p></fn></table-wrap-foot></table-wrap><p>In a study by Arafah [<xref rid="bvac185-B164" ref-type="bibr">164</xref>], 20&#8197;mg of oral hydrocortisone 2 to 4&#8197;hours. prior to surgery resulted in a baseline cortisol of 14.8&#8197;ug/dL in those with central AI. The administration of 25&#8197;mg of hydrocortisone IV resulted in a nadir serum cortisol range of 16 to 34&#8197;ug/dL at 6&#8197;hours, which was higher with subsequent injections. In this setting, cortisol half-life was longer, volume of distribution increased, and clearance was lower in patients with AI compared to healthy individuals. This study suggests that patients with AI who are administered 20&#8197;mg of hydrocortisone 2 to 4 hours prior to intubation have a baseline cortisol level comparable to healthy individuals with an intact HPA axis. Subsequently, providing 25&#8197;mg of IV hydrocortisone every 6&#8197;hours for 24&#8197;hours, followed by 15&#8197;mg every 6&#8197;hours or 24&#8197;hours, resulted in no adverse events or symptoms suggestive of AI. This study did not include patients with GC-induced AI, but the same concepts may be applied as most subjects in this study had secondary AI. Additionally, cardiac surgery procedures were not included. The results are in agreement with the trend that our current practices provide higher perioperative GC doses than needed [<xref rid="bvac185-B165" ref-type="bibr">165</xref>]. Considering this, 15 to 25&#8197;mg of hydrocortisone IV every 6&#8197;hours (60-100&#8197;mg/day) should provide enough perioperative coverage for even moderate to major operations in patients suspected to have GC-induced AI. Others have shown that continuous hydrocortisone infusion provides more stable cortisol concentrations during major stress without significant peaks and troughs that may be seen with intramuscular or IV administrations. This approach requires an additional IV infusion line, and no data indicate that continuous hydrocortisone infusion prevents adrenal crisis or is associated with lower adverse events compared to intermittent hydrocortisone injections [<xref rid="bvac185-B70" ref-type="bibr">70</xref>]. We have summarized our perioperative approach in <xref rid="bvac185-T5" ref-type="table">Table 5</xref>.</p><p>There is little data in perioperative management of pregnant patients on chronic GC. Cortisol levels increase throughout pregnancy secondary to increased CBG and to the HPA axis stimulation by placental CRH. The dose of GC replacement does not usually need to be increased during the first and second trimesters, but an increase in GC dosage of 20% to 40% from the 24th week forward is generally recommended [<xref rid="bvac185-B166" ref-type="bibr">166</xref>]. Accordingly, a 50% higher perioperative parenteral GC coverage, especially during the third trimester, and delivery seems reasonable. Careful perioperative monitoring of the hemodynamic status of pregnant women and their fetus is critical [<xref rid="bvac185-B166" ref-type="bibr">166&#8211;168</xref>].</p></sec></sec><sec sec-type="conclusions" id="bvac185-s5"><title>Conclusions</title><p>Perioperative management of patients on GCs has been a major topic of discussion for over 70 years. It is clear that assessment of the HPA axis in patients who have stopped GC therapy before surgery is necessary. However, despite the progress in our understanding of the stress response and hormonal behavior perioperatively, there is significant heterogeneity in clinical practice in terms of GCs dosing. In most cases, excess GCs are administered, which may result in several adverse events. The current literature supports that in patients undergoing a surgical procedure, continuing the daily dose of GCs along with a short course of perioperative IV GCs based on the level of anticipated surgical stress is adequate. In most perioperative scenarios, administration of &#8804;100&#8197;mg/day hydrocortisone with a rapid taper to preoperative GC dose is sufficient. Close monitoring for any evidence of hemodynamic instability is fundamental. Finally, there is a need for large prospective studies to optimize the perioperative management of patients on GCs to avoid any clinically significant AI-related event and do no harm.</p></sec></body><back><sec id="bvac185-s6"><title>Funding</title><p>None declared.</p></sec><sec id="bvac185-s7"><title>Disclosures</title><p>None.</p></sec><sec sec-type="data-availability" id="bvac185-s8"><title>Data Availability</title><p>Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.</p></sec><ref-list id="ref1"><title>References</title><ref id="bvac185-B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Overman</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Yeh</surname><given-names>JY</given-names></string-name>, <string-name name-style="western"><surname>Deal</surname><given-names>CL</given-names></string-name></person-group>. <article-title>Prevalence of oral glucocorticoid usage in the United States: a general population perspective</article-title>. <source>Arthritis Care Res</source>. <year>2013</year>;<volume>65</volume>(<issue>2</issue>):<fpage>294</fpage>&#8211;<lpage>298</lpage>. doi:<pub-id pub-id-type="doi">10.1002/acr.21796</pub-id><pub-id pub-id-type="pmid">22807233</pub-id></mixed-citation></ref><ref id="bvac185-B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mebrahtu</surname><given-names>TF</given-names></string-name>, <string-name name-style="western"><surname>Morgan</surname><given-names>AW</given-names></string-name>, <string-name name-style="western"><surname>Keeley</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Baxter</surname><given-names>PD</given-names></string-name>, <string-name name-style="western"><surname>Stewart</surname><given-names>PM</given-names></string-name>, <string-name name-style="western"><surname>Pujades-Rodriguez</surname><given-names>M</given-names></string-name></person-group>. <article-title>Dose dependency of iatrogenic glucocorticoid excess and adrenal insufficiency and mortality: a cohort study in England</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2019</year>;<volume>104</volume>(<issue>9</issue>):<fpage>3757</fpage>&#8211;<lpage>3767</lpage>. doi:<pub-id pub-id-type="doi">10.1210/jc.2019-00153</pub-id><pub-id pub-id-type="pmid">31009052</pub-id><pub-id pub-id-type="pmcid">PMC6656418</pub-id></mixed-citation></ref><ref id="bvac185-B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Swingle</surname><given-names>WW</given-names></string-name>, <string-name name-style="western"><surname>Parkins</surname><given-names>WM</given-names></string-name>, <string-name name-style="western"><surname>Taylor</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Hays</surname><given-names>HW</given-names></string-name></person-group>. <article-title>A study of the circulatory failure and shock following trauma to the healthy, vigorous adrenalectomized dog</article-title>. <source>Am J Physiol</source>. <year>1938</year>;<volume>124</volume>(<issue>1</issue>):<fpage>22</fpage>&#8211;<lpage>29</lpage>. doi:<pub-id pub-id-type="doi">10.1152/ajplegacy.1938.124.1.22</pub-id></mixed-citation></ref><ref id="bvac185-B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Swingle</surname><given-names>WW</given-names></string-name>, <string-name name-style="western"><surname>Remington</surname><given-names>JW</given-names></string-name>, <string-name name-style="western"><surname>Drill</surname><given-names>VA</given-names></string-name>, <string-name name-style="western"><surname>Kleinberg</surname><given-names>W</given-names></string-name></person-group>. <article-title>Differences among adrenal steroids with respect to their efficacy in protecting the adrenalectomized dog against circulatory failure</article-title>. <source>Am J Physiol</source>. <year>1942</year>;<volume>136</volume>(<issue>4</issue>):<fpage>567</fpage>&#8211;<lpage>576</lpage>. doi:<pub-id pub-id-type="doi">10.1152/ajplegacy.1942.136.4.567</pub-id></mixed-citation></ref><ref id="bvac185-B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fraser</surname><given-names>CG</given-names></string-name>, <string-name name-style="western"><surname>Preuss</surname><given-names>FS</given-names></string-name>, <string-name name-style="western"><surname>Bigford</surname><given-names>W</given-names></string-name></person-group>. <article-title>Adrenal atrophy and irreversible shock associated with cortisone therapy</article-title>. <source>JAMA</source>. <year>1952</year>;<volume>149</volume>(<issue>17</issue>):<fpage>1542</fpage>&#8211;<lpage>1543</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.1952.72930340001009</pub-id><pub-id pub-id-type="pmid">14945970</pub-id></mixed-citation></ref><ref id="bvac185-B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lewis</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Robinson</surname><given-names>RF</given-names></string-name>, <string-name name-style="western"><surname>Yee</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hacker</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Eisen</surname><given-names>G</given-names></string-name></person-group>. <article-title>Fatal adrenal cortical insufficiency precipitated by surgery during prolonged continuous cortisone treatment</article-title>. <source>Ann Intern Med</source>. <year>1953</year>;<volume>39</volume>(<issue>1</issue>):<fpage>116</fpage>&#8211;<lpage>126</lpage>. doi:<pub-id pub-id-type="doi">10.7326/0003-4819-39-1-116</pub-id><pub-id pub-id-type="pmid">13065993</pub-id></mixed-citation></ref><ref id="bvac185-B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Salassa</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Bennett</surname><given-names>WA</given-names></string-name>, <string-name name-style="western"><surname>Keating</surname><given-names>FR</given-names><suffix>Jr</suffix></string-name>, <string-name name-style="western"><surname>Sprague</surname><given-names>RG</given-names></string-name></person-group>. <article-title>Postoperative adrenal cortical insufficiency. Occurrence in patients previously treated with cortisone</article-title>. <source>JAMA</source>. <year>1953</year>;<volume>152</volume>(<issue>16</issue>):<fpage>1509</fpage>&#8211;<lpage>1515</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.1953.03690160009004</pub-id><pub-id pub-id-type="pmid">13061310</pub-id></mixed-citation></ref><ref id="bvac185-B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Salem</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Tainsh</surname><given-names>RE</given-names></string-name>, <string-name name-style="western"><surname>Bromberg</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Loriaux</surname><given-names>DL</given-names></string-name>, <string-name name-style="western"><surname>Chernow</surname><given-names>B</given-names></string-name></person-group>. <article-title>Perioperative glucocorticoid coverage: a reassessment 42 years after emergence of a problem</article-title>. <source>Ann Surg</source>. <year>1994</year>;<volume>219</volume>(<issue>4</issue>):<fpage>416</fpage>&#8211;<lpage>425</lpage>. doi:<pub-id pub-id-type="doi">10.1097/00000658-199404000-00013</pub-id><pub-id pub-id-type="pmid">8161268</pub-id><pub-id pub-id-type="pmcid">PMC1243159</pub-id></mixed-citation></ref><ref id="bvac185-B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Groleau</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Morin</surname><given-names>SN</given-names></string-name>, <string-name name-style="western"><surname>Vautour</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Amar-Zifkin</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Bessissow</surname><given-names>A</given-names></string-name></person-group>. <article-title>Perioperative corticosteroid administration: a systematic review and descriptive analysis</article-title>. <source>Perioper Med</source>. <year>2018</year>;<volume>7</volume>(<issue>1</issue>):<fpage>1</fpage>&#8211;<lpage>8</lpage>. doi:<pub-id pub-id-type="doi">10.1186/s13741-018-0092-9</pub-id><pub-id pub-id-type="pmcid">PMC5994041</pub-id><pub-id pub-id-type="pmid">29977522</pub-id></mixed-citation></ref><ref id="bvac185-B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Laugesen</surname><given-names>AK</given-names></string-name>, <string-name name-style="western"><surname>Broersen</surname><given-names>LHA</given-names></string-name>, <string-name name-style="western"><surname>Hansen</surname><given-names>SB</given-names></string-name>, <string-name name-style="western"><surname>Olaf</surname><given-names>M</given-names></string-name></person-group>. <article-title>Glucocorticoid-induced adrenal insufficiency: replace while we wait for evidence?</article-title><source>Eur J Endocrinol</source>. <year>2021</year>;<volume>184</volume>(<issue>4</issue>):<fpage>R112</fpage>&#8211;<lpage>R122</lpage>. doi:<pub-id pub-id-type="doi">10.1530/EJE-20-1199</pub-id><pub-id pub-id-type="pmid">33449912</pub-id></mixed-citation></ref><ref id="bvac185-B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Seo</surname><given-names>KH</given-names></string-name></person-group>. <article-title>Perioperative glucocorticoid management based on current evidence</article-title>. <source>Anesth Pain Med</source>. <year>2021</year>;<volume>16</volume>(<issue>1</issue>):<fpage>8</fpage>&#8211;<lpage>15</lpage>. doi:<pub-id pub-id-type="doi">10.17085/apm.20089</pub-id><pub-id pub-id-type="pmcid">PMC7861897</pub-id><pub-id pub-id-type="pmid">33445232</pub-id></mixed-citation></ref><ref id="bvac185-B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tamez-P&#233;rez</surname><given-names>HE</given-names></string-name></person-group>. <article-title>Steroid hyperglycemia: prevalence, early detection and therapeutic recommendations: a narrative review</article-title>. <source>World J Diabetes</source>. <year>2015</year>;<volume>6</volume>(<issue>8</issue>):<fpage>1073</fpage>. doi:<pub-id pub-id-type="doi">10.4239/wjd.v6.i8.1073</pub-id><pub-id pub-id-type="pmid">26240704</pub-id><pub-id pub-id-type="pmcid">PMC4515447</pub-id></mixed-citation></ref><ref id="bvac185-B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Carolina</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Kato</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Khanh</surname><given-names>VC</given-names></string-name>, <etal>et al</etal></person-group><article-title>Glucocorticoid impaired the wound healing ability of endothelial progenitor cells by reducing the expression of CXCR4 in the PGE2 pathway</article-title>. <source>Front Med</source>. <year>2019</year>;<volume>5</volume>:<fpage>1</fpage>&#8211;<lpage>17</lpage>. doi:<pub-id pub-id-type="doi">10.3389/fmed.2018.00276</pub-id><pub-id pub-id-type="pmcid">PMC6173212</pub-id><pub-id pub-id-type="pmid">30324106</pub-id></mixed-citation></ref><ref id="bvac185-B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Ahmet</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ward</surname><given-names>L</given-names></string-name>, <etal>et al</etal></person-group><article-title>A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy</article-title>. <source>Allergy, Asthma Clin Immunol</source>. <year>2013</year>;<volume>9</volume>(<issue>1</issue>):<fpage>1</fpage>&#8211;<lpage>25</lpage>. doi:<pub-id pub-id-type="doi">10.1186/1710-1492-9-30</pub-id><pub-id pub-id-type="pmid">23947590</pub-id><pub-id pub-id-type="pmcid">PMC3765115</pub-id></mixed-citation></ref><ref id="bvac185-B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Esteban N</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Loughlin</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Yergey</surname><given-names>AL</given-names></string-name>, <etal>et al</etal></person-group><article-title>Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry</article-title>. <source>J Clin Endocrinol Metab</source>. <year>1991</year>;<volume>72</volume>(<issue>1</issue>):<fpage>39</fpage>&#8211;<lpage>45</lpage>. doi:<pub-id pub-id-type="doi">10.1210/jcem-72-1-39</pub-id><pub-id pub-id-type="pmid">1986026</pub-id></mixed-citation></ref><ref id="bvac185-B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dorin</surname><given-names>RI</given-names></string-name>, <string-name name-style="western"><surname>Qiao</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Qualls</surname><given-names>CR</given-names></string-name>, <string-name name-style="western"><surname>Urban</surname><given-names>FK</given-names></string-name></person-group>. <article-title>Estimation of maximal cortisol secretion rate in healthy humans</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2012</year>;<volume>97</volume>(<issue>4</issue>):<fpage>1285</fpage>&#8211;<lpage>1293</lpage>. doi:<pub-id pub-id-type="doi">10.1210/jc.2011-2227</pub-id><pub-id pub-id-type="pmid">22337905</pub-id><pub-id pub-id-type="pmcid">PMC3319177</pub-id></mixed-citation></ref><ref id="bvac185-B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Axelrod</surname><given-names>L</given-names></string-name></person-group>. <article-title>Perioperative management of patients treated with glucocorticoids</article-title>. <source>Endocrinol Metab Clin North Am</source>. <year>2003</year>;<volume>32</volume>(<issue>2</issue>):<fpage>367</fpage>&#8211;<lpage>383</lpage>. doi:<pub-id pub-id-type="doi">10.1016/s0889-8529(03)00008-2</pub-id><pub-id pub-id-type="pmid">12800537</pub-id></mixed-citation></ref><ref id="bvac185-B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Perogamvros</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Ray</surname><given-names>DW</given-names></string-name>, <string-name name-style="western"><surname>Trainer</surname><given-names>PJ</given-names></string-name></person-group>. <article-title>Regulation of cortisol bioavailability&#8212;effects on hormone measurement and action</article-title>. <source>Nat Rev Endocrinol</source>. <year>2012</year>;<volume>8</volume>(<issue>12</issue>):<fpage>717</fpage>&#8211;<lpage>727</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nrendo.2012.134</pub-id><pub-id pub-id-type="pmid">22890008</pub-id></mixed-citation></ref><ref id="bvac185-B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Russell</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Lightman</surname><given-names>S</given-names></string-name></person-group>. <article-title>The human stress response</article-title>. <source>Nat Rev Endocrinol</source>. <year>2019</year>;<volume>15</volume>(<issue>9</issue>):<fpage>525</fpage>&#8211;<lpage>534</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41574-019-0228-0</pub-id><pub-id pub-id-type="pmid">31249398</pub-id></mixed-citation></ref><ref id="bvac185-B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Oakley</surname><given-names>RH</given-names></string-name>, <string-name name-style="western"><surname>Cidlowski</surname><given-names>JA</given-names></string-name></person-group>. <article-title>The biology of the glucocorticoid receptor: new signaling mechanisms in health and disease</article-title>. <source>J Allergy Clin Immunol</source>. <year>2013</year>;<volume>132</volume>(<issue>5</issue>):<fpage>1033</fpage>&#8211;<lpage>1044</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jaci.2013.09.007</pub-id><pub-id pub-id-type="pmid">24084075</pub-id><pub-id pub-id-type="pmcid">PMC4084612</pub-id></mixed-citation></ref><ref id="bvac185-B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gjerstad</surname><given-names>JK</given-names></string-name>, <string-name name-style="western"><surname>Lightman</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Spiga</surname><given-names>F</given-names></string-name></person-group>. <article-title>Role of glucocorticoid negative feedback in the regulation of HPA axis pulsatility</article-title>. <source>Stress</source>. <year>2018</year>;<volume>21</volume>(<issue>5</issue>):<fpage>403</fpage>&#8211;<lpage>416</lpage>. doi:<pub-id pub-id-type="doi">10.1080/10253890.2018.1470238</pub-id><pub-id pub-id-type="pmid">29764284</pub-id><pub-id pub-id-type="pmcid">PMC6220752</pub-id></mixed-citation></ref><ref id="bvac185-B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Song</surname><given-names>IH</given-names></string-name>, <string-name name-style="western"><surname>Buttgereit</surname><given-names>F</given-names></string-name></person-group>. <article-title>Non-genomic glucocorticoid effects to provide the basis for new drug developments</article-title>. <source>Mol Cell Endocrinol</source>. <year>2006</year>;<volume>246</volume>(<issue>1-2</issue>):<fpage>142</fpage>&#8211;<lpage>146</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.mce.2005.11.012</pub-id><pub-id pub-id-type="pmid">16388891</pub-id></mixed-citation></ref><ref id="bvac185-B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mir</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Chin</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Riddell</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Beaudry</surname><given-names>JL</given-names></string-name></person-group>. <article-title>Genomic and non-genomic actions of glucocorticoids on adipose tissue lipid metabolism</article-title>. <source>Int J Mol Sci</source>. <year>2021</year>;<volume>22</volume>(<issue>16</issue>):<fpage>8503</fpage>. doi:<pub-id pub-id-type="doi">10.3390/ijms22168503</pub-id><pub-id pub-id-type="pmid">34445209</pub-id><pub-id pub-id-type="pmcid">PMC8395154</pub-id></mixed-citation></ref><ref id="bvac185-B24"><label>24</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Soto-Rivera</surname><given-names>CL</given-names></string-name>, <string-name name-style="western"><surname>Majzoub</surname><given-names>JA</given-names></string-name></person-group>. <part-title>Adrenocorticotrophin</part-title>. In: <source>The Pituitary</source>. <edition>4th ed</edition>. <publisher-name>Elsevier</publisher-name>; <year>2017</year>:<fpage>47</fpage>&#8211;<lpage>83</lpage>. doi:<pub-id pub-id-type="doi">10.1016/B978-0-12-804169-7.00003-9</pub-id></mixed-citation></ref><ref id="bvac185-B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jaattela</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ilvesmaki</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Voutilainen</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Stenman</surname><given-names>U-H</given-names></string-name>, <string-name name-style="western"><surname>Saksela</surname><given-names>E</given-names></string-name></person-group>. <article-title>Tumor necrosis factor as a potent inhibitor of adrenocorticotropin-induced cortisol production and steroidogenic P450 enzyme gene expression in cultured human fetal adrenal cells</article-title>. <source>Endocrinology</source>. <year>1991</year>;<volume>128</volume>(<issue>1</issue>):<fpage>623</fpage>&#8211;<lpage>629</lpage>. doi:<pub-id pub-id-type="doi">10.1210/endo-128-1-623</pub-id><pub-id pub-id-type="pmid">1702707</pub-id></mixed-citation></ref><ref id="bvac185-B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bateman</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Singh</surname><given-names>AVA</given-names></string-name>, <string-name name-style="western"><surname>Kral</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Solomon</surname><given-names>S</given-names></string-name></person-group>. <article-title>The immune-hypothalamic-pituitary-adrenal axis</article-title>. <source>Endocr Rev</source>. <year>1989</year>;<volume>10</volume>(<issue>1</issue>):<fpage>92</fpage>&#8211;<lpage>112</lpage>. doi:<pub-id pub-id-type="doi">10.1210/edrv-10-1-92</pub-id><pub-id pub-id-type="pmid">2666113</pub-id></mixed-citation></ref><ref id="bvac185-B27"><label>27</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Lechan</surname><given-names>RM</given-names></string-name></person-group>. <part-title>Neuroendocrinology</part-title>. In: <source>Williams Textbook of Endocrinology</source>. <edition>14th ed.</edition><publisher-name>Elsevier</publisher-name>, <year>2019</year>:<fpage>58</fpage>&#8211;<lpage>66</lpage>.</mixed-citation></ref><ref id="bvac185-B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Seckl</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Chapman</surname><given-names>KE</given-names></string-name></person-group>. <article-title>The 11&#946;-hydroxysteroid dehydrogenase system, a determinant of glucocorticoid and mineralocorticoid action</article-title>. <source>Eur J Biochem</source>. <year>1997</year>;<volume>249</volume>(<issue>2</issue>):<fpage>361</fpage>&#8211;<lpage>364</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1432-1033.1997.t01-1-00361.x</pub-id><pub-id pub-id-type="pmid">9370341</pub-id></mixed-citation></ref><ref id="bvac185-B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Prete</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Yan</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Al-Tarrah</surname><given-names>K</given-names></string-name>, <etal>et al</etal></person-group><article-title>The cortisol stress response induced by surgery: a systematic review and meta-analysis</article-title>. <source>Clin Endocrinol (Oxf)</source>. <year>2018</year>;<volume>89</volume>(<issue>5</issue>):<fpage>554</fpage>&#8211;<lpage>567</lpage>. doi:<pub-id pub-id-type="doi">10.1111/cen.13820</pub-id><pub-id pub-id-type="pmid">30047158</pub-id></mixed-citation></ref><ref id="bvac185-B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chernow</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Alexander</surname><given-names>HR</given-names></string-name>, <string-name name-style="western"><surname>Smallridge</surname><given-names>RC</given-names></string-name>, <etal>et al</etal></person-group><article-title>Hormonal responses to graded surgical stress</article-title>. <source>Arch Intern Med</source>. <year>1987</year>;<volume>147</volume>(<issue>7</issue>):<fpage>1273</fpage>&#8211;<lpage>1278</lpage>. doi:<pub-id pub-id-type="doi">10.1001/archinte.1987.00370070087013</pub-id><pub-id pub-id-type="pmid">3606284</pub-id></mixed-citation></ref><ref id="bvac185-B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Khoo</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Boshier</surname><given-names>PR</given-names></string-name>, <string-name name-style="western"><surname>Freethy</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group><article-title>Redefining the stress cortisol response to surgery</article-title>. <source>Clin Endocrinol (Oxf)</source>. <year>2017</year>;<volume>87</volume>(<issue>5</issue>):<fpage>451</fpage>&#8211;<lpage>458</lpage>. doi:<pub-id pub-id-type="doi">10.1111/cen.13439</pub-id><pub-id pub-id-type="pmid">28758231</pub-id></mixed-citation></ref><ref id="bvac185-B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Donati</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ruzzi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Adrario</surname><given-names>E</given-names></string-name>, <etal>et al</etal></person-group><article-title>A new and feasible model for predicting operative risk</article-title>. <source>Br J Anaesth</source>. <year>2004</year>;<volume>93</volume>(<issue>3</issue>):<fpage>393</fpage>&#8211;<lpage>399</lpage>. doi:<pub-id pub-id-type="doi">10.1093/bja/aeh210</pub-id><pub-id pub-id-type="pmid">15220171</pub-id></mixed-citation></ref><ref id="bvac185-B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kehlet</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Binder</surname><given-names>C</given-names></string-name></person-group>. <article-title>Adrenocortical function and clinical course during and after surgery in unsupplemented glucocorticoid-treated patients</article-title>. <source>Br J Anaesth</source>. <year>1973</year>;<volume>45</volume>(<issue>10</issue>):<fpage>1043</fpage>&#8211;<lpage>1048</lpage>. doi:<pub-id pub-id-type="doi">10.1093/bja/45.10.1043</pub-id><pub-id pub-id-type="pmid">4772640</pub-id></mixed-citation></ref><ref id="bvac185-B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Plumpton</surname><given-names>FS</given-names></string-name>, <string-name name-style="western"><surname>Besser</surname><given-names>GM</given-names></string-name>, <string-name name-style="western"><surname>Cole</surname><given-names>PV</given-names></string-name></person-group>. <article-title>Corticosteroid treatment and surgery. 1. An investigation of the indication for steroid cover</article-title>. <source>Anaesthesia</source>. <year>1969</year>;<volume>24</volume>(<issue>1</issue>):<fpage>3</fpage>&#8211;<lpage>11</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1365-2044.1969.tb02798.x</pub-id><pub-id pub-id-type="pmid">5762010</pub-id></mixed-citation></ref><ref id="bvac185-B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kehlet</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Binder</surname><given-names>C</given-names></string-name></person-group>. <article-title>Alterations in distribution volume and biological half-life of cortisol during major surgery</article-title>. <source>J Clin Endocrinol Metab</source>. <year>1973</year>;<volume>36</volume>(<issue>2</issue>):<fpage>330</fpage>&#8211;<lpage>333</lpage>. doi:<pub-id pub-id-type="doi">10.1210/jcem-36-2-330</pub-id><pub-id pub-id-type="pmid">4683188</pub-id></mixed-citation></ref><ref id="bvac185-B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cooper</surname><given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Nelson</surname><given-names>DH</given-names></string-name></person-group>. <article-title>Acth levels in plasma in preoperative and surgically stressed patients</article-title>. <source>J Clin Invest</source>. <year>1962</year>;<volume>41</volume>(<issue>8</issue>):<fpage>1599</fpage>&#8211;<lpage>1605</lpage>. doi:<pub-id pub-id-type="doi">10.1172/JCI104618</pub-id><pub-id pub-id-type="pmid">16695880</pub-id><pub-id pub-id-type="pmcid">PMC291078</pub-id></mixed-citation></ref><ref id="bvac185-B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Udelsman</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Norton</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Jelenich</surname><given-names>SE</given-names></string-name>, <etal>et al</etal></person-group><article-title>Responses of the hypothalamic-pituitary-adrenal and renin-angiotensin axes and the sympathetic system during controlled surgical and anesthetic stress</article-title>. <source>J Clin Endocrinol Metab</source>. <year>1987</year>;<volume>64</volume>(<issue>5</issue>):<fpage>986</fpage>&#8211;<lpage>994</lpage>. doi:<pub-id pub-id-type="doi">10.1210/jcem-64-5-986</pub-id><pub-id pub-id-type="pmid">3031124</pub-id></mixed-citation></ref><ref id="bvac185-B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Naito</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Fukata</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Tamai</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group><article-title>Biphasic changes in hypothalamo-pituitary-adrenal function during the early recovery period after major abdominal surgery</article-title>. <source>J Clin Endocrinol Metab</source>. <year>1991</year>;<volume>73</volume>(<issue>1</issue>):<fpage>111</fpage>&#8211;<lpage>117</lpage>. doi:<pub-id pub-id-type="doi">10.1210/jcem-73-1-111</pub-id><pub-id pub-id-type="pmid">1646214</pub-id></mixed-citation></ref><ref id="bvac185-B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Boonen</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Vervenne</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Meersseman</surname><given-names>P</given-names></string-name>, <etal>et al</etal></person-group><article-title>Reduced cortisol metabolism during critical illness</article-title>. <source>N Engl J Med</source>. <year>2013</year>;<volume>368</volume>(<issue>16</issue>):<fpage>1477</fpage>&#8211;<lpage>1488</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa1214969</pub-id><pub-id pub-id-type="pmid">23506003</pub-id><pub-id pub-id-type="pmcid">PMC4413428</pub-id></mixed-citation></ref><ref id="bvac185-B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Redgate</surname><given-names>ES</given-names></string-name></person-group>. <article-title>Spinal cord and ACTH release in adrenalectomized rats following electrical stimulation</article-title>. <source>Endocrinology</source>. <year>1962</year>;<volume>70</volume>(<issue>2</issue>):<fpage>263</fpage>&#8211;<lpage>266</lpage>. doi:<pub-id pub-id-type="doi">10.1210/endo-70-2-263</pub-id><pub-id pub-id-type="pmid">14490937</pub-id></mixed-citation></ref><ref id="bvac185-B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Raff</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Norton</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Flemma</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Findling</surname><given-names>JW</given-names></string-name></person-group>. <article-title>Inhibition of the adrenocorticotropin response to surgery in humans: interaction between dexamethasone and fentanyl</article-title>. <source>J Clin Endocrinol Metab</source>. <year>1987</year>;<volume>65</volume>(<issue>2</issue>):<fpage>295</fpage>&#8211;<lpage>298</lpage>. doi:<pub-id pub-id-type="doi">10.1210/jcem-65-2-295</pub-id><pub-id pub-id-type="pmid">3036903</pub-id></mixed-citation></ref><ref id="bvac185-B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Engeland</surname><given-names>WC</given-names></string-name>, <string-name name-style="western"><surname>Arnhold</surname><given-names>MM</given-names></string-name></person-group>. <article-title>Neural circuitry in the regulation of adrenal corticosterone rhythmicity</article-title>. <source>Endocrine</source>. <year>2005</year>;<volume>28</volume>(<issue>3</issue>):<fpage>325</fpage>&#8211;<lpage>331</lpage>. doi:<pub-id pub-id-type="doi">10.1385/ENDO:28:3:325</pub-id><pub-id pub-id-type="pmid">16388123</pub-id></mixed-citation></ref><ref id="bvac185-B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gibbison</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Spiga</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Walker</surname><given-names>JJ</given-names></string-name>, <etal>et al</etal></person-group><article-title>Dynamic pituitary-adrenal interactions in response to cardiac surgery</article-title>. <source>Crit Care Med</source>. <year>2015</year>;<volume>43</volume>(<issue>4</issue>):<fpage>791</fpage>&#8211;<lpage>800</lpage>. doi:<pub-id pub-id-type="doi">10.1097/CCM.0000000000000773</pub-id><pub-id pub-id-type="pmid">25517478</pub-id><pub-id pub-id-type="pmcid">PMC4359905</pub-id></mixed-citation></ref><ref id="bvac185-B44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Vogeser</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Felbinger</surname><given-names>TW</given-names></string-name>, <string-name name-style="western"><surname>Kilger</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>R&#246;ll</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Fraunberger</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Jacob</surname><given-names>K</given-names></string-name></person-group>. <article-title>Corticosteroid-binding globulin and free cortisol in the early postoperative period after cardiac surgery</article-title>. <source>Clin Biochem</source>. <year>1999</year>;<volume>32</volume>(<issue>3</issue>):<fpage>213</fpage>&#8211;<lpage>216</lpage>. doi:<pub-id pub-id-type="doi">10.1016/s0009-9120(99)00009-0</pub-id><pub-id pub-id-type="pmid">10383083</pub-id></mixed-citation></ref><ref id="bvac185-B45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tsigos</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Kyrou</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Chrousus</surname><given-names>GP</given-names></string-name>, <string-name name-style="western"><surname>Papanicolaou</surname><given-names>DA</given-names></string-name></person-group>. <article-title>Prolonged suppression of corticosteroid-binding globulin by recombinant human interleukin-6 in man</article-title>. <source>J Clin Endocrinol Metab</source>. <year>1998</year>;<volume>83</volume>(<issue>9</issue>):<fpage>3379</fpage>. doi:<pub-id pub-id-type="doi">10.1210/jcem.83.9.5100-5</pub-id><pub-id pub-id-type="pmid">9745461</pub-id></mixed-citation></ref><ref id="bvac185-B46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fritz</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Levine</surname><given-names>R</given-names></string-name></person-group>. <article-title>Action of adrenal cortical steroids and nor-epinephrine on vascular responses of stress in adrenalectomized rats</article-title>. <source>Am J Physiol</source>. <year>1951</year>;<volume>165</volume>(<issue>2</issue>):<fpage>456</fpage>&#8211;<lpage>465</lpage>. doi:<pub-id pub-id-type="doi">10.1152/ajplegacy.1951.165.2.456</pub-id><pub-id pub-id-type="pmid">14838134</pub-id></mixed-citation></ref><ref id="bvac185-B47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>L</given-names></string-name></person-group>. <article-title>Glucocorticoids and vascular reactivity</article-title>. <source>Curr Vasc Pharmacol</source>. <year>2005</year>;<volume>2</volume>(<issue>1</issue>):<fpage>1</fpage>&#8211;<lpage>12</lpage>. doi:<pub-id pub-id-type="doi">10.2174/1570161043476483</pub-id><pub-id pub-id-type="pmid">15320828</pub-id></mixed-citation></ref><ref id="bvac185-B48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ullian</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Walsh</surname><given-names>LG</given-names></string-name>, <string-name name-style="western"><surname>Morinelli</surname><given-names>TA</given-names></string-name></person-group>. <article-title>Potentiation of angiotensin II action by corticosteroids in vascular tissue</article-title>. <source>Cardiovasc Res</source>. <year>1996</year>;<volume>32</volume>(<issue>2</issue>):<fpage>266</fpage>&#8211;<lpage>273</lpage>. doi:<pub-id pub-id-type="doi">10.1016/0008-6363(96)00053-3</pub-id><pub-id pub-id-type="pmid">8796113</pub-id></mixed-citation></ref><ref id="bvac185-B49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sakaue</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hoffman</surname><given-names>BB</given-names></string-name></person-group>. <article-title>Glucocorticoids induce transcription and expression of the &#945;1B adrenergic receptor gene in DTT1 MF-2 smooth muscle cells</article-title>. <source>J Clin Invest</source>. <year>1991</year>;<volume>88</volume>(<issue>2</issue>):<fpage>385</fpage>&#8211;<lpage>389</lpage>. doi:<pub-id pub-id-type="doi">10.1172/JCI115315</pub-id><pub-id pub-id-type="pmid">1650792</pub-id><pub-id pub-id-type="pmcid">PMC295342</pub-id></mixed-citation></ref><ref id="bvac185-B50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>TN</given-names></string-name>, <string-name name-style="western"><surname>Knight</surname><given-names>JK</given-names></string-name>, <string-name name-style="western"><surname>Goodwin</surname><given-names>JE</given-names></string-name></person-group>. <article-title>The glucocorticoid receptor in cardiovascular health and disease</article-title>. <source>Cells</source>. <year>2019</year>;<volume>8</volume>(<issue>10</issue>):<fpage>1</fpage>&#8211;<lpage>21</lpage>. doi:<pub-id pub-id-type="doi">10.3390/cells8101227</pub-id><pub-id pub-id-type="pmcid">PMC6829609</pub-id><pub-id pub-id-type="pmid">31601045</pub-id></mixed-citation></ref><ref id="bvac185-B51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Stith</surname><given-names>RD</given-names></string-name>, <string-name name-style="western"><surname>Bhaskar</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Reddy</surname><given-names>YS</given-names></string-name>, <string-name name-style="western"><surname>Brackett</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Lerner</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Wilson</surname><given-names>MF</given-names></string-name></person-group>. <article-title>Cardiovascular changes in chronically adrenalectomized conscious rats</article-title>. <source>Circ Shock</source>. <year>1989</year>;<volume>28</volume>(<issue>4</issue>):<fpage>395</fpage>&#8211;<lpage>403</lpage>.<pub-id pub-id-type="pmid">2776284</pub-id></mixed-citation></ref><ref id="bvac185-B52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bouachour</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Tirot</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Varache</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Gouello</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Harry</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Alquier</surname><given-names>P</given-names></string-name></person-group>. <article-title>Hemodynamic changes in acute adrenal insufficiency</article-title>. <source>Intensive Care Med</source>. <year>1994</year>;<volume>20</volume>(<issue>2</issue>):<fpage>138</fpage>&#8211;<lpage>141</lpage>. doi:<pub-id pub-id-type="doi">10.1007/BF01707669</pub-id><pub-id pub-id-type="pmid">8201094</pub-id></mixed-citation></ref><ref id="bvac185-B53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dorin</surname><given-names>RI</given-names></string-name>, <string-name name-style="western"><surname>Kearns</surname><given-names>PJ</given-names></string-name></person-group>. <article-title>High output circulatory failure in acute adrenal insufficiency</article-title>. <source>Crit Care Med</source>. <year>1988</year>;<volume>16</volume>(<issue>3</issue>):<fpage>296</fpage>&#8211;<lpage>297</lpage>. doi:<pub-id pub-id-type="doi">10.1097/00003246-198803000-00019</pub-id><pub-id pub-id-type="pmid">2830078</pub-id></mixed-citation></ref><ref id="bvac185-B54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Weil</surname><given-names>MH</given-names></string-name></person-group>. <article-title>The cardiovascular effects of corticosteroids</article-title>. <source>Circulation</source>. <year>1962</year>;<volume>XXV</volume>(<issue>4</issue>):<fpage>718</fpage>&#8211;<lpage>725</lpage>. doi:<pub-id pub-id-type="doi">10.1161/01.cir.25.4.718</pub-id><pub-id pub-id-type="pmid">14040205</pub-id></mixed-citation></ref><ref id="bvac185-B55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lown</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Arons</surname><given-names>WL</given-names></string-name>, <string-name name-style="western"><surname>Ganong</surname><given-names>WF</given-names></string-name>, <string-name name-style="western"><surname>Vazifdar</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Levine</surname><given-names>SA</given-names></string-name></person-group>. <article-title>Adrenal steroids and auriculoventricular conduction</article-title>. <source>Am Heart J</source>. <year>1955</year>;<volume>50</volume>(<issue>5</issue>):<fpage>760</fpage>&#8211;<lpage>769</lpage>. doi:<pub-id pub-id-type="doi">10.1016/0002-8703(55)90183-6</pub-id><pub-id pub-id-type="pmid">13258501</pub-id></mixed-citation></ref><ref id="bvac185-B56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gould</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Reddy</surname><given-names>CV</given-names></string-name>, <string-name name-style="western"><surname>Reidel</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Gomprecht</surname><given-names>RF</given-names></string-name></person-group>. <article-title>The effect of pharmacologic doses of steroids on atrioventricular conduction in man</article-title>. <source>J Clin Pharmacol</source>. <year>1975</year>;<volume>15</volume>(<issue>4</issue>):<fpage>262</fpage>&#8211;<lpage>268</lpage>. doi:<pub-id pub-id-type="doi">10.1002/j.1552-4604.1975.tb01446.x</pub-id><pub-id pub-id-type="pmid">1127132</pub-id></mixed-citation></ref><ref id="bvac185-B57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Devareddy</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Sawicki</surname><given-names>KT</given-names></string-name>, <string-name name-style="western"><surname>Choudhury</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wilcox</surname><given-names>JE</given-names></string-name></person-group>. <article-title>Reversible biventricular heart failure due to primary adrenal insufficiency</article-title>. <source>JACC Case Rep</source>. <year>2020</year>;<volume>2</volume>(<issue>3</issue>):<fpage>411</fpage>&#8211;<lpage>413</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jaccas.2019.12.039</pub-id><pub-id pub-id-type="pmid">32363353</pub-id><pub-id pub-id-type="pmcid">PMC7194194</pub-id></mixed-citation></ref><ref id="bvac185-B58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>P&#233;rez-Alvarez</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Hern&#225;ndez-Vivanco</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Albillos</surname><given-names>A</given-names></string-name></person-group>. <article-title>Past, present and future of human chromaffin cells: role in physiology and therapeutics</article-title>. <source>Cell Mol Neurobiol</source>. <year>2010</year>;<volume>30</volume>(<issue>8</issue>):<fpage>1407</fpage>&#8211;<lpage>1415</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10571-010-9582-0</pub-id><pub-id pub-id-type="pmid">21107679</pub-id><pub-id pub-id-type="pmcid">PMC11498861</pub-id></mixed-citation></ref><ref id="bvac185-B59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Merke</surname><given-names>DP</given-names></string-name>, <string-name name-style="western"><surname>Chrousos</surname><given-names>GP</given-names></string-name>, <string-name name-style="western"><surname>Eisenhofer</surname><given-names>G</given-names></string-name>, <etal>et al</etal></person-group><article-title>Adrenomedullary dysplasia and hypofunction in patients with classic 21-hydroxylase deficiency</article-title>. <source>N Engl J Med</source>. <year>2000</year>;<volume>343</volume>(<issue>19</issue>):<fpage>1362</fpage>&#8211;<lpage>1368</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJM200011093431903</pub-id><pub-id pub-id-type="pmid">11070100</pub-id></mixed-citation></ref><ref id="bvac185-B60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dempster</surname><given-names>WJ</given-names></string-name></person-group>. <article-title>The nature of the venous system in the adrenal gland</article-title>. <source>Tohoku J Exp Med</source>. <year>1974</year>;<volume>112</volume>(<issue>1</issue>):<fpage>63</fpage>&#8211;<lpage>77</lpage>. doi:<pub-id pub-id-type="doi">10.1620/tjem.112.63</pub-id><pub-id pub-id-type="pmid">4838242</pub-id></mixed-citation></ref><ref id="bvac185-B61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zuckerman-Levin</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Tiosano</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Eisenhofer</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Bornstein</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hochberg</surname><given-names>Z</given-names></string-name></person-group>. <article-title>The importance of adrenocortical glucocorticoids for adrenomedullary and physiological response to stress: a study in isolated glucocorticoid deficiency</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2001</year>;<volume>86</volume>(<issue>12</issue>):<fpage>5920</fpage>&#8211;<lpage>5924</lpage>. doi:<pub-id pub-id-type="doi">10.1210/jcem.86.12.8106</pub-id><pub-id pub-id-type="pmid">11739465</pub-id></mixed-citation></ref><ref id="bvac185-B62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hahner</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Loeffler</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bleicken</surname><given-names>B</given-names></string-name>, <etal>et al</etal></person-group><article-title>Epidemiology of adrenal crisis in chronic adrenal insufficiency: the need for new prevention strategies</article-title>. <source>Eur J Endocrinol</source>. <year>2010</year>;<volume>162</volume>(<issue>3</issue>):<fpage>597</fpage>&#8211;<lpage>602</lpage>. doi:<pub-id pub-id-type="doi">10.1530/EJE-09-0884</pub-id><pub-id pub-id-type="pmid">19955259</pub-id></mixed-citation></ref><ref id="bvac185-B63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>He</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Findling</surname><given-names>JW</given-names></string-name>, <string-name name-style="western"><surname>Auchus</surname><given-names>RJ</given-names></string-name></person-group>. <article-title>Glucocorticoid withdrawal syndrome following treatment of endogenous Cushing syndrome</article-title>. <source>Pituitary</source>. <year>2022</year>;<volume>25</volume>(<issue>3</issue>):<fpage>393</fpage>&#8211;<lpage>403</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11102-022-01218-y</pub-id><pub-id pub-id-type="pmid">35471718</pub-id><pub-id pub-id-type="pmcid">PMC9170649</pub-id></mixed-citation></ref><ref id="bvac185-B64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Axelrod</surname><given-names>L</given-names></string-name></person-group>. <article-title>Glucocorticoid therapy</article-title>. <source>Medicine (Baltimore)</source>. <year>1976</year>;<volume>55</volume>(<issue>1</issue>):<fpage>39</fpage>&#8211;<lpage>65</lpage>. doi:<pub-id pub-id-type="doi">10.1097/00005792-197601000-00003</pub-id><pub-id pub-id-type="pmid">173974</pub-id></mixed-citation></ref><ref id="bvac185-B65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Czock</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Keller</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Rasche</surname><given-names>FM</given-names></string-name>, <string-name name-style="western"><surname>Ulla</surname><given-names>H</given-names></string-name></person-group>. <article-title>Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids</article-title>. <source>Clin Pharmacokinet</source>. <year>2005</year>;<volume>44</volume>(<issue>1</issue>):<fpage>61</fpage>&#8211;<lpage>98</lpage>. doi:<pub-id pub-id-type="doi">10.2165/00003088-200544010-00003</pub-id><pub-id pub-id-type="pmid">15634032</pub-id></mixed-citation></ref><ref id="bvac185-B66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chilkoti</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Singh</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Mohta</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kumar Saxena</surname><given-names>A</given-names></string-name></person-group>. <article-title>Perioperative &#8220;stress dose&#8221; of corticosteroid: pharmacological and clinical perspective</article-title>. <source>J Anaesthesiol Clin Pharmacol</source>. <year>2019</year>;<volume>35</volume>(<issue>2</issue>):<fpage>147</fpage>&#8211;<lpage>152</lpage>. doi:<pub-id pub-id-type="doi">10.4103/joacp.JOACP_242_17</pub-id><pub-id pub-id-type="pmid">31303699</pub-id><pub-id pub-id-type="pmcid">PMC6598572</pub-id></mixed-citation></ref><ref id="bvac185-B67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Argenti</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Jensen</surname><given-names>BK</given-names></string-name>, <string-name name-style="western"><surname>Hensel</surname><given-names>R</given-names></string-name>, <etal>et al</etal></person-group><article-title>A mass balance study to evaluate the biotransformation and excretion of [14C]-triamcinolone acetonide following oral administration</article-title>. <source>J Clin Pharmacol</source>. <year>2000</year>;<volume>40</volume>(<issue>7</issue>):<fpage>770</fpage>&#8211;<lpage>780</lpage>. doi:<pub-id pub-id-type="doi">10.1177/00912700022009413</pub-id><pub-id pub-id-type="pmid">10883419</pub-id></mixed-citation></ref><ref id="bvac185-B68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>M&#246;llmann</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Hochhaus</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Rohatagi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Barth</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Derendorf</surname><given-names>H</given-names></string-name></person-group>. <article-title>Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone</article-title>. <source>Pharm Res</source><year>1995</year>;<volume>12</volume>(<issue>7</issue>):<fpage>1096</fpage>&#8211;<lpage>1100</lpage>. doi:<pub-id pub-id-type="doi">10.1023/a:1016287104656</pub-id><pub-id pub-id-type="pmid">7494809</pub-id></mixed-citation></ref><ref id="bvac185-B69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Derendorf</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>M&#246;llmann</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Barth</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>M&#246;llmann</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Tunn</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Krieg</surname><given-names>M</given-names></string-name></person-group>. <article-title>Pharmacokinetics and oral bioavailability of hydrocortisone</article-title>. <source>J Clin Pharmacol</source>. <year>1991</year>;<volume>31</volume>(<issue>5</issue>):<fpage>473</fpage>&#8211;<lpage>476</lpage>. doi:<pub-id pub-id-type="doi">10.1002/j.1552-4604.1991.tb01906.x</pub-id><pub-id pub-id-type="pmid">2050835</pub-id></mixed-citation></ref><ref id="bvac185-B70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Prete</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Taylor</surname><given-names>AE</given-names></string-name>, <string-name name-style="western"><surname>Bancos</surname><given-names>I</given-names></string-name>, <etal>et al</etal></person-group><article-title>Prevention of adrenal crisis: cortisol responses to major stress compared to stress dose hydrocortisone delivery</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2020</year>;<volume>105</volume>(<issue>7</issue>):<fpage>2262</fpage>&#8211;<lpage>2274</lpage>. doi:<pub-id pub-id-type="doi">10.1210/clinem/dgaa133</pub-id><pub-id pub-id-type="pmid">32170323</pub-id><pub-id pub-id-type="pmcid">PMC7241266</pub-id></mixed-citation></ref><ref id="bvac185-B71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hahner</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Burger-Stritt</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Allolio</surname><given-names>B</given-names></string-name></person-group>. <article-title>Subcutaneous hydrocortisone administration for emergency use in adrenal insufficiency</article-title>. <source>Eur J Endocrinol</source>. <year>2013</year>;<volume>169</volume>(<issue>2</issue>):<fpage>147</fpage>&#8211;<lpage>154</lpage>. doi:<pub-id pub-id-type="doi">10.1530/EJE-12-1057</pub-id><pub-id pub-id-type="pmid">23672956</pub-id></mixed-citation></ref><ref id="bvac185-B72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Paragliola</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Papi</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Pontecorvi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Corsello</surname><given-names>SM</given-names></string-name></person-group>. <article-title>Treatment with synthetic glucocorticoids and the hypothalamus-pituitary-adrenal axis</article-title>. <source>Int J Mol Sci</source>. <year>2017</year>;<volume>18</volume>(<issue>10</issue>):<fpage>2201</fpage>. doi:<pub-id pub-id-type="doi">10.3390/ijms18102201</pub-id><pub-id pub-id-type="pmid">29053578</pub-id><pub-id pub-id-type="pmcid">PMC5666882</pub-id></mixed-citation></ref><ref id="bvac185-B73"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>De Maeyer</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Lapauw</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Hoorens</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Geerts</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Van Vlierberghe</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Verhelst</surname><given-names>X</given-names></string-name></person-group>. <article-title>Secondary adrenal insufficiency after treatment with budesonide for autoimmune hepatitis</article-title>. <source>Case Rep Gastroenterol</source>. <year>2018</year>;<volume>12</volume>(<issue>3</issue>):<fpage>597</fpage>&#8211;<lpage>601</lpage>. doi:<pub-id pub-id-type="doi">10.1159/000492204</pub-id><pub-id pub-id-type="pmid">30386198</pub-id><pub-id pub-id-type="pmcid">PMC6206950</pub-id></mixed-citation></ref><ref id="bvac185-B74"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Berkelhammer</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Trabolsi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Andrejic</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Yasmeen</surname><given-names>T</given-names></string-name></person-group>. <article-title>Severe adrenal insufficiency complicating budesonide therapy for Crohn's disease</article-title>. <source>Inflamm Bowel Dis</source>. <year>2011</year>;<volume>17</volume>(<issue>4</issue>):<fpage>1053</fpage>&#8211;<lpage>1054</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ibd.21399</pub-id><pub-id pub-id-type="pmid">20629105</pub-id></mixed-citation></ref><ref id="bvac185-B75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Karamchandani</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Leathem</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Sinz</surname><given-names>EH</given-names></string-name></person-group>. <article-title>Acute adrenal insufficiency in the perioperative period: a case report</article-title>. <source>A&amp;A Pract</source>. <year>2019</year>;<volume>12</volume>(<issue>3</issue>):<fpage>63</fpage>&#8211;<lpage>65</lpage>. doi:<pub-id pub-id-type="doi">10.1213/XAA.0000000000000846</pub-id><pub-id pub-id-type="pmid">30020102</pub-id></mixed-citation></ref><ref id="bvac185-B76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Knudsen</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Christiansen</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Lorentzen</surname><given-names>JE</given-names></string-name></person-group>. <article-title>Hypotension during and after operation in glucocorticoid-treated patients</article-title>. <source>Br J Anaesth</source>. <year>1981</year>;<volume>53</volume>(<issue>3</issue>):<fpage>295</fpage>&#8211;<lpage>301</lpage>. doi:<pub-id pub-id-type="doi">10.1093/bja/53.3.295</pub-id><pub-id pub-id-type="pmid">7470364</pub-id></mixed-citation></ref><ref id="bvac185-B77"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Joseph</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Hunter</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Ray</surname><given-names>DW</given-names></string-name>, <string-name name-style="western"><surname>Dixon</surname><given-names>WG</given-names></string-name></person-group>. <article-title>Systemic glucocorticoid therapy and adrenal insufficiency in adults: a systematic review</article-title>. <source>Semin Arthritis Rheum</source>. <year>2016</year>;<volume>46</volume>(<issue>1</issue>):<fpage>133</fpage>&#8211;<lpage>141</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.semarthrit.2016.03.001</pub-id><pub-id pub-id-type="pmid">27105755</pub-id><pub-id pub-id-type="pmcid">PMC4987145</pub-id></mixed-citation></ref><ref id="bvac185-B78"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Schlaghecke</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Kornely</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Santen</surname><given-names>RT</given-names></string-name>, <string-name name-style="western"><surname>Ridderskamp</surname><given-names>P</given-names></string-name></person-group>. <article-title>The effect of long-term glucocorticoid therapy on pituitary-adrenal responses to exogenous corticotropin-releasing hormone</article-title>. <source>N Engl J Med</source>. <year>1992</year>;<volume>326</volume>(<issue>4</issue>):<fpage>226</fpage>&#8211;<lpage>230</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJM199201233260403</pub-id><pub-id pub-id-type="pmid">1309389</pub-id></mixed-citation></ref><ref id="bvac185-B79"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Spiegel</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Oliff</surname><given-names>AI</given-names></string-name>, <string-name name-style="western"><surname>Echelberger</surname><given-names>CK</given-names></string-name>, <string-name name-style="western"><surname>Poplack</surname><given-names>DG</given-names></string-name></person-group>. <article-title>Adrenal suppression after short-term corticosteroid therapy</article-title>. <source>Lancet</source>. <year>1979</year>;<volume>1</volume>(<issue>8124</issue>):<fpage>630</fpage>&#8211;<lpage>633</lpage>. doi:<pub-id pub-id-type="doi">10.1016/s0140-6736(79)91077-8</pub-id><pub-id pub-id-type="pmid">85870</pub-id></mixed-citation></ref><ref id="bvac185-B80"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Karangizi</surname><given-names>AHK</given-names></string-name>, <string-name name-style="western"><surname>Al-shaghana</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Logan</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group><article-title>Glucocorticoid induced adrenal insufficiency is common in steroid treated glomerular diseases&#8212;proposed strategy for screening and management</article-title>. <source>BMC Nephrol</source>. <year>2019</year>;<volume>20</volume>(<issue>1</issue>):<fpage>1</fpage>&#8211;<lpage>7</lpage>. doi:<pub-id pub-id-type="doi">10.1186/s12882-019-1354-6</pub-id><pub-id pub-id-type="pmid">31060510</pub-id><pub-id pub-id-type="pmcid">PMC6503364</pub-id></mixed-citation></ref><ref id="bvac185-B81"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Broersen</surname><given-names>LHA</given-names></string-name>, <string-name name-style="western"><surname>Pereira</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>J&#248;rgensen</surname><given-names>JOL</given-names></string-name>, <string-name name-style="western"><surname>Dekkers</surname><given-names>OM</given-names></string-name></person-group>. <article-title>Adrenal insufficiency in corticosteroids use: systematic review and meta-analysis</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2015</year>;<volume>100</volume>(<issue>6</issue>):<fpage>2171</fpage>&#8211;<lpage>2180</lpage>. doi:<pub-id pub-id-type="doi">10.1210/jc.2015-1218</pub-id><pub-id pub-id-type="pmid">25844620</pub-id></mixed-citation></ref><ref id="bvac185-B82"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Krasner</surname><given-names>AS</given-names></string-name></person-group>. <article-title>Glucocorticoid-induced adrenal insufficiency</article-title>. <source>JAMA</source>. <year>1999</year>;<volume>282</volume>(<issue>7</issue>):<fpage>671</fpage>&#8211;<lpage>676</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.282.7.671</pub-id><pub-id pub-id-type="pmid">10517721</pub-id></mixed-citation></ref><ref id="bvac185-B83"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Park</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Kwak</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Chung</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hong</surname><given-names>HJ</given-names></string-name>, <string-name name-style="western"><surname>Chon</surname><given-names>JY</given-names></string-name>, <string-name name-style="western"><surname>Moon</surname><given-names>HS</given-names></string-name></person-group>. <article-title>Incidence of adrenal insufficiency and Cushing's syndrome after long-term epidural steroid injections over six months or longer: a preliminary study</article-title>. <source>J Pain Res</source>. <year>2020</year>;<volume>13</volume>:<fpage>1505</fpage>&#8211;<lpage>1514</lpage>. doi:<pub-id pub-id-type="doi">10.2147/JPR.S252278</pub-id><pub-id pub-id-type="pmid">32606916</pub-id><pub-id pub-id-type="pmcid">PMC7321692</pub-id></mixed-citation></ref><ref id="bvac185-B84"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chon</surname><given-names>JY</given-names></string-name>, <string-name name-style="western"><surname>Moon</surname><given-names>HS</given-names></string-name></person-group>. <article-title>Salivary cortisol concentration changes after epidural steroid injection</article-title>. <source>Pain Physician</source>. <year>2012</year>;<volume>15</volume>(<issue>6</issue>):<fpage>461</fpage>&#8211;<lpage>466</lpage>. doi:<pub-id pub-id-type="doi">10.36076/ppj.2012/15/461</pub-id><pub-id pub-id-type="pmid">23159961</pub-id></mixed-citation></ref><ref id="bvac185-B85"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>LaRochelle</surname><given-names>GE</given-names></string-name>, <string-name name-style="western"><surname>LaRochelle</surname><given-names>AG</given-names></string-name>, <string-name name-style="western"><surname>Ratner</surname><given-names>RE</given-names></string-name>, <string-name name-style="western"><surname>Borenstein</surname><given-names>DG</given-names></string-name></person-group>. <article-title>Recovery of the hypothalamic-pituitary-adrenal (HPA) axis in patients with rheumatic diseases receiving low-dose prednisone</article-title>. <source>Am J Med</source>. <year>1993</year>;<volume>95</volume>(<issue>3</issue>):<fpage>258</fpage>&#8211;<lpage>264</lpage>. doi:<pub-id pub-id-type="doi">10.1016/0002-9343(93)90277-v</pub-id><pub-id pub-id-type="pmid">8368224</pub-id></mixed-citation></ref><ref id="bvac185-B86"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Carella</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Srivastava</surname><given-names>LS</given-names></string-name>, <string-name name-style="western"><surname>Gossain</surname><given-names>VV</given-names></string-name>, <string-name name-style="western"><surname>Rovner</surname><given-names>DR</given-names></string-name></person-group>. <article-title>Hypothalamic-pituitary-adrenal function one week after a short burst of steroid therapy</article-title>. <source>J Clin Endocrinol Metab</source>. <year>1993</year>;<volume>76</volume>(<issue>5</issue>):<fpage>1188</fpage>&#8211;<lpage>1191</lpage>. doi:<pub-id pub-id-type="doi">10.1210/jcem.76.5.8388401</pub-id><pub-id pub-id-type="pmid">8388401</pub-id></mixed-citation></ref><ref id="bvac185-B87"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Klinefelter</surname><given-names>HF</given-names></string-name>, <string-name name-style="western"><surname>Winkenwerder</surname><given-names>WL</given-names></string-name>, <string-name name-style="western"><surname>Bledsoe</surname><given-names>T</given-names></string-name></person-group>. <article-title>Single daily dose prednisone therapy</article-title>. <source>JAMA</source>. <year>1979</year>;<volume>241</volume>(<issue>25</issue>):<fpage>2721</fpage>&#8211;<lpage>2723</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.1979.03290510029021</pub-id><pub-id pub-id-type="pmid">221687</pub-id></mixed-citation></ref><ref id="bvac185-B88"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nichols</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Nugent</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Tyler</surname><given-names>FH</given-names></string-name></person-group>. <article-title>Diurnal variation in suppression of adrenal function by glucocorticoids</article-title>. <source>J Clin Endocrinol Metab</source>. <year>1965</year>;<volume>25</volume>(<issue>3</issue>):<fpage>343</fpage>&#8211;<lpage>349</lpage>. doi:<pub-id pub-id-type="doi">10.1210/jcem-25-3-343</pub-id><pub-id pub-id-type="pmid">14264259</pub-id></mixed-citation></ref><ref id="bvac185-B89"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Myles</surname><given-names>AB</given-names></string-name>, <string-name name-style="western"><surname>Schiller</surname><given-names>LFG</given-names></string-name>, <string-name name-style="western"><surname>Glass</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Daly</surname><given-names>JR</given-names></string-name></person-group>. <article-title>Single daily dose corticosteroid treatment</article-title>. <source>Ann Rheum Dis</source>. <year>1976</year>;<volume>35</volume>(<issue>1</issue>):<fpage>73</fpage>&#8211;<lpage>76</lpage>. doi:<pub-id pub-id-type="doi">10.1136/ard.35.1.73</pub-id><pub-id pub-id-type="pmid">1275584</pub-id><pub-id pub-id-type="pmcid">PMC1006511</pub-id></mixed-citation></ref><ref id="bvac185-B90"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ackerman</surname><given-names>GL</given-names></string-name>, <string-name name-style="western"><surname>Nolan</surname><given-names>CM</given-names></string-name></person-group>. <article-title>Adrenocortical responsiveness after alternate-day corticosteroid therapy</article-title>. <source>N Engl J Med</source>. <year>1968</year>;<volume>278</volume>(<issue>8</issue>):<fpage>405</fpage>&#8211;<lpage>409</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJM196802222780801</pub-id><pub-id pub-id-type="pmid">5636662</pub-id></mixed-citation></ref><ref id="bvac185-B91"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Johnston</surname><given-names>PC</given-names></string-name>, <string-name name-style="western"><surname>Lansang</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Chatterjee</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kennedy</surname><given-names>L</given-names></string-name></person-group>. <article-title>Intra-articular glucocorticoid injections and their effect on hypothalamic-pituitary-adrenal (HPA)-axis function</article-title>. <source>Endocrine</source>. <year>2015</year>;<volume>48</volume>(<issue>2</issue>):<fpage>410</fpage>&#8211;<lpage>416</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s12020-014-0409-5</pub-id><pub-id pub-id-type="pmid">25182149</pub-id></mixed-citation></ref><ref id="bvac185-B92"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Prete</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Bancos</surname><given-names>I</given-names></string-name></person-group>. <article-title>Glucocorticoid induced adrenal insufficiency</article-title>. <source>BMJ</source>. <year>2021</year>;<volume>374</volume>(<issue>1380</issue>):<fpage>1</fpage>&#8211;<lpage>20</lpage>. doi:<pub-id pub-id-type="doi">10.1136/bmj.n1380</pub-id><pub-id pub-id-type="pmid">34253540</pub-id></mixed-citation></ref><ref id="bvac185-B93"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Habib</surname><given-names>GS</given-names></string-name></person-group>. <article-title>Systemic effects of intra-articular corticosteroids</article-title>. <source>Clin Rheumatol</source>. <year>2009</year>;<volume>28</volume>(<issue>7</issue>):<fpage>749</fpage>&#8211;<lpage>756</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10067-009-1135-x</pub-id><pub-id pub-id-type="pmid">19252817</pub-id></mixed-citation></ref><ref id="bvac185-B94"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Habib</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Jabbour</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Artul</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hakim</surname><given-names>G</given-names></string-name></person-group>. <article-title>Intra-articular methylprednisolone acetate injection at the knee joint and the hypothalamic-pituitary-adrenal axis: a randomized controlled study</article-title>. <source>Clin Rheumatol</source>. <year>2014</year>;<volume>33</volume>(<issue>1</issue>):<fpage>99</fpage>&#8211;<lpage>103</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10067-013-2374-4</pub-id><pub-id pub-id-type="pmid">23982564</pub-id></mixed-citation></ref><ref id="bvac185-B95"><label>95</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Habib</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Khazin</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Jabbour</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group><article-title>Simultaneous bilateral knee injection of methylprednisolone acetate and the hypothalamic-pituitary adrenal axis: a single-blind case-control study</article-title>. <source>J Investig Med</source>. <year>2014</year>;<volume>62</volume>(<issue>3</issue>):<fpage>621</fpage>&#8211;<lpage>626</lpage>. doi:<pub-id pub-id-type="doi">10.2310/JIM.0000000000000048</pub-id><pub-id pub-id-type="pmid">24430212</pub-id></mixed-citation></ref><ref id="bvac185-B96"><label>96</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Iranmanesh</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gullapalli</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Singh</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Veldhuis</surname><given-names>JD</given-names></string-name></person-group>. <article-title>Hypothalamo-pituitary-adrenal axis after a single epidural triamcinolone injection</article-title>. <source>Endocrine</source>. <year>2017</year>;<volume>57</volume>(<issue>2</issue>):<fpage>308</fpage>&#8211;<lpage>313</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s12020-017-1357-7</pub-id><pub-id pub-id-type="pmid">28674775</pub-id><pub-id pub-id-type="pmcid">PMC5554884</pub-id></mixed-citation></ref><ref id="bvac185-B97"><label>97</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hamrahian</surname><given-names>AH</given-names></string-name>, <string-name name-style="western"><surname>Fleseriu</surname><given-names>M</given-names></string-name></person-group>. <article-title>Evaluation and management of adrenal insufficiency in critically ill patients: disease state review</article-title>. <source>Endocr Pract</source>. <year>2017</year>;<volume>23</volume>(<issue>6</issue>):<fpage>716</fpage>&#8211;<lpage>725</lpage>. doi:<pub-id pub-id-type="doi">10.4158/EP161720.RA</pub-id><pub-id pub-id-type="pmid">28332876</pub-id></mixed-citation></ref><ref id="bvac185-B98"><label>98</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lipworth</surname><given-names>BJ</given-names></string-name></person-group>. <article-title>Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis</article-title>. <source>Arch Intern Med</source>. <year>1999</year>;<volume>159</volume>(<issue>9</issue>):<fpage>941</fpage>&#8211;<lpage>955</lpage>. doi:<pub-id pub-id-type="doi">10.1001/archinte.159.9.941</pub-id><pub-id pub-id-type="pmid">10326936</pub-id></mixed-citation></ref><ref id="bvac185-B99"><label>99</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gilbertson</surname><given-names>EO</given-names></string-name>, <string-name name-style="western"><surname>Spellman</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Piacquadio</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Mim</surname><given-names>I</given-names></string-name></person-group>. <article-title>Super potent topical corticosteroid use associated with adrenal suppression: clinical considerations</article-title><year>1998</year>;<volume>38</volume>(<issue>2 Pt 2</issue>):<fpage>318</fpage>&#8211;<lpage>321</lpage>. doi:<pub-id pub-id-type="doi">10.1016/s0190-9622(98)70573-0</pub-id><pub-id pub-id-type="pmid">9486706</pub-id></mixed-citation></ref><ref id="bvac185-B100"><label>100</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lawlor</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Ramabala</surname><given-names>K</given-names></string-name></person-group>. <article-title>Iatrogenic Cushing&#8217;s syndrome&#8212;a cautionary tale</article-title>. <source>Clin Exp Dermatol</source>. <year>1984</year>;<volume>9</volume>(<issue>3</issue>):<fpage>286</fpage>&#8211;<lpage>289</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1365-2230.1984.tb00798.x</pub-id><pub-id pub-id-type="pmid">6329563</pub-id></mixed-citation></ref><ref id="bvac185-B101"><label>101</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Walsh</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Aeling</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Huff</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Weston</surname><given-names>WL</given-names></string-name></person-group>. <article-title>Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids</article-title>. <source>J Am Acad Dermatol</source>. <year>1993</year>;<volume>29</volume>(<issue>3</issue>):<fpage>501</fpage>&#8211;<lpage>503</lpage>. doi:<pub-id pub-id-type="doi">10.1016/s0190-9622(08)82011-7</pub-id><pub-id pub-id-type="pmid">8349876</pub-id></mixed-citation></ref><ref id="bvac185-B102"><label>102</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dekio</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Morita</surname><given-names>E</given-names></string-name></person-group>. <article-title>The weight of a finger-tip unit of ointment in 5-gram tubes</article-title>. <source>J Dermatolog Treat</source>. <year>2011</year>;<volume>22</volume>(<issue>5</issue>):<fpage>302</fpage>&#8211;<lpage>303</lpage>. doi:<pub-id pub-id-type="doi">10.3109/09546631003797098</pub-id><pub-id pub-id-type="pmid">20673156</pub-id></mixed-citation></ref><ref id="bvac185-B103"><label>103</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Levin</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Maibach</surname><given-names>HI</given-names></string-name></person-group>. <article-title>Topical corticosteroid-induced adrenocortical insufficiency: clinical implications</article-title>. <source>Am J Clin Dermatol</source>. <year>2002</year>;<volume>3</volume>(<issue>3</issue>):<fpage>141</fpage>&#8211;<lpage>147</lpage>. doi:<pub-id pub-id-type="doi">10.2165/00128071-200203030-00001</pub-id><pub-id pub-id-type="pmid">11978135</pub-id></mixed-citation></ref><ref id="bvac185-B104"><label>104</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Afandi</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Toumeh</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Saadi</surname><given-names>HF</given-names></string-name></person-group>. <article-title>Cushing's syndrome caused by unsupervised use of ocular glucocorticoids</article-title>. <source>Endocr Pract</source>. <year>2003</year>;<volume>9</volume>(<issue>6</issue>):<fpage>526</fpage>&#8211;<lpage>529</lpage>. doi:<pub-id pub-id-type="doi">10.4158/EP.9.6.526</pub-id><pub-id pub-id-type="pmid">14715481</pub-id></mixed-citation></ref><ref id="bvac185-B105"><label>105</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Luman</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Gray</surname><given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Pendek</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Palmer</surname><given-names>KR</given-names></string-name></person-group>. <article-title>Prednisolone metasulphobenzoate foam retention enemas suppress the hypothalamo-pituitary-adrenal axis</article-title>. <source>Aliment Pharmacol Ther</source>. <year>1994</year>;<volume>8</volume>(<issue>2</issue>):<fpage>255</fpage>&#8211;<lpage>258</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1365-2036.1994.tb00284.x</pub-id><pub-id pub-id-type="pmid">8038357</pub-id></mixed-citation></ref><ref id="bvac185-B106"><label>106</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Canalejo</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Pacheco</surname><given-names>MS</given-names></string-name></person-group>. <article-title>Cushing syndrome due to ritonavir-fluticasone interaction</article-title>. <source>CMAJ</source>. <year>2012</year>;<volume>184</volume>(<issue>15</issue>):<fpage>1714</fpage>. doi:<pub-id pub-id-type="doi">10.1503/cmaj.111315</pub-id><pub-id pub-id-type="pmid">22586335</pub-id><pub-id pub-id-type="pmcid">PMC3478357</pub-id></mixed-citation></ref><ref id="bvac185-B107"><label>107</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>AM</given-names></string-name></person-group>. <article-title>Ritonavir and fluticasone: beware of this potentially fatal combination</article-title>. <source>J Pediatr</source>. <year>2006</year>;<volume>148</volume>(<issue>3</issue>):<fpage>294</fpage>&#8211;<lpage>295</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jpeds.2005.12.057</pub-id><pub-id pub-id-type="pmid">16615953</pub-id></mixed-citation></ref><ref id="bvac185-B108"><label>108</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Samaras</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Pett</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Gowers</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>McMurchie</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Cooper</surname><given-names>DA</given-names></string-name></person-group>. <article-title>Iatrogenic Cushing's syndrome with osteoporosis and secondary adrenal failure in human immunodeficiency virus-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2005</year>;<volume>90</volume>(<issue>7</issue>):<fpage>4394</fpage>&#8211;<lpage>4398</lpage>. doi:<pub-id pub-id-type="doi">10.1210/jc.2005-0036</pub-id><pub-id pub-id-type="pmid">15755851</pub-id></mixed-citation></ref><ref id="bvac185-B109"><label>109</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Elliot</surname><given-names>ER</given-names></string-name>, <string-name name-style="western"><surname>Theodoraki</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Jain</surname><given-names>LR</given-names></string-name>, <etal>et al</etal></person-group><article-title>Iatrogenic Cushing's syndrome due to drug interaction between glucocorticoids and the ritonavir or cobicistat containing HIV therapies</article-title>. <source>Clin Med (Lond)</source>. <year>2016</year>;<volume>16</volume>(<issue>5</issue>):<fpage>412</fpage>&#8211;<lpage>418</lpage>. doi:<pub-id pub-id-type="doi">10.7861/clinmedicine.16-5-412</pub-id><pub-id pub-id-type="pmid">27697800</pub-id><pub-id pub-id-type="pmcid">PMC6297313</pub-id></mixed-citation></ref><ref id="bvac185-B110"><label>110</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Daveluy</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Raignoux</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Miremont-Salam&#233;</surname><given-names>G</given-names></string-name>, <etal>et al</etal></person-group><article-title>Drug interactions between inhaled corticosteroids and enzymatic inhibitors</article-title>. <source>Eur J Clin Pharmacol</source>. <year>2009</year>;<volume>65</volume>(<issue>7</issue>):<fpage>743</fpage>&#8211;<lpage>745</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00228-009-0653-4</pub-id><pub-id pub-id-type="pmid">19399485</pub-id></mixed-citation></ref><ref id="bvac185-B111"><label>111</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Duman</surname><given-names>AK</given-names></string-name>, <string-name name-style="western"><surname>Fulco</surname><given-names>PP</given-names></string-name></person-group>. <article-title>Adrenal insufficiency with voriconazole and inhaled/intranasal corticosteroids: case report and systematic review</article-title>. <source>J Pharm Pract</source>. <year>2017</year>;<volume>30</volume>(<issue>4</issue>):<fpage>459</fpage>&#8211;<lpage>463</lpage>. doi:<pub-id pub-id-type="doi">10.1177/0897190016646510</pub-id><pub-id pub-id-type="pmid">27147607</pub-id></mixed-citation></ref><ref id="bvac185-B112"><label>112</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Donegan</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Bancos</surname><given-names>I</given-names></string-name></person-group>. <article-title>Opioid-induced adrenal insufficiency</article-title>. <source>Mayo Clin Proc</source>. <year>2018</year>;<volume>93</volume>(<issue>7</issue>):<fpage>937</fpage>&#8211;<lpage>944</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.mayocp.2018.04.010</pub-id><pub-id pub-id-type="pmid">29976376</pub-id></mixed-citation></ref><ref id="bvac185-B113"><label>113</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Cunningham</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Gilliam</surname><given-names>WP</given-names></string-name>, <string-name name-style="western"><surname>Loukianova</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Donegan</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Bancos</surname><given-names>I</given-names></string-name></person-group>. <article-title>Prevalence of opioid-induced adrenal insufficiency in patients taking chronic opioids</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2020</year>;<volume>105</volume>(<issue>10</issue>):<fpage>e3766</fpage>&#8211;<lpage>e3775</lpage>. doi:<pub-id pub-id-type="doi">10.1210/clinem/dgaa499</pub-id><pub-id pub-id-type="pmid">32866966</pub-id><pub-id pub-id-type="pmcid">PMC7470471</pub-id></mixed-citation></ref><ref id="bvac185-B114"><label>114</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Vongsavan</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Pavasuthipaisit</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Rakprasitkul</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kitiyanant</surname><given-names>Y</given-names></string-name></person-group>. <article-title>Beta-endorphin, ACTH, and cortisol secretion in man during standardized oral surgical stress and effect of diazepam</article-title>. <source>J Med Assoc Thail</source>. <year>1990</year>;<volume>73</volume>(<issue>8</issue>):<fpage>443</fpage>&#8211;<lpage>449</lpage>.<pub-id pub-id-type="pmid">2175764</pub-id></mixed-citation></ref><ref id="bvac185-B115"><label>115</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gram</surname><given-names>LF</given-names></string-name>, <string-name name-style="western"><surname>Christensen</surname><given-names>P</given-names></string-name></person-group>. <article-title>Benzodiazepine suppression of cortisol secretion: a measure of anxiolytic activity?</article-title><source>Pharmacopsychiatry</source>. <year>1986</year>;<volume>19</volume>(<issue>1</issue>):<fpage>19</fpage>&#8211;<lpage>22</lpage>. doi:<pub-id pub-id-type="doi">10.1055/s-2007-1017143</pub-id><pub-id pub-id-type="pmid">2870513</pub-id></mixed-citation></ref><ref id="bvac185-B116"><label>116</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kalogeras</surname><given-names>KT</given-names></string-name>, <string-name name-style="western"><surname>Calogero</surname><given-names>AE</given-names></string-name>, <string-name name-style="western"><surname>Kuribayiashi</surname><given-names>T</given-names></string-name>, <etal>et al</etal></person-group><article-title>In vitro and in vivo effects of the triazolobenzodiazepine alprazolam on hypothalamic pituitary-adrenal function: pharmacological and clinical implications</article-title>. <source>J Clin Endocrinol Metab</source>. <year>1990</year>;<volume>70</volume>(<issue>5</issue>):<fpage>1462</fpage>&#8211;<lpage>1471</lpage>. doi:<pub-id pub-id-type="doi">10.1210/jcem-70-5-1462</pub-id><pub-id pub-id-type="pmid">2159487</pub-id></mixed-citation></ref><ref id="bvac185-B117"><label>117</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Simpson</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Tomlinson</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wass</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Dean</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Arlt</surname><given-names>W</given-names></string-name></person-group>. <article-title>Guidance for the prevention and emergency management of adult patients with adrenal insufficiency</article-title>. <source>Clin Med (Lond)</source>. <year>2020</year>;<volume>20</volume>(<issue>4</issue>):<fpage>371</fpage>&#8211;<lpage>378</lpage>. doi:<pub-id pub-id-type="doi">10.7861/clinmed.2019-0324</pub-id><pub-id pub-id-type="pmid">32675141</pub-id><pub-id pub-id-type="pmcid">PMC7385786</pub-id></mixed-citation></ref><ref id="bvac185-B118"><label>118</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Symreng</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Karlberg</surname><given-names>BE</given-names></string-name>, <string-name name-style="western"><surname>K&#229;gedal</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Schildt</surname><given-names>B</given-names></string-name></person-group>. <article-title>Physiological cortisol substitution of long-term steroid-treated patients undergoing major surgery</article-title>. <source>Br J Anaesth</source>. <year>1981</year>;<volume>53</volume>(<issue>9</issue>):<fpage>949</fpage>&#8211;<lpage>954</lpage>. doi:<pub-id pub-id-type="doi">10.1093/bja/53.9.949</pub-id><pub-id pub-id-type="pmid">6793052</pub-id></mixed-citation></ref><ref id="bvac185-B119"><label>119</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dorin</surname><given-names>RI</given-names></string-name>, <string-name name-style="western"><surname>Qualls</surname><given-names>CR</given-names></string-name>, <string-name name-style="western"><surname>Crapo</surname><given-names>LM</given-names></string-name></person-group>. <article-title>Diagnosis of adrenal insufficiency</article-title>. <source>Ann Intern Med</source>. <year>2003</year>;<volume>139</volume>(<issue>3</issue>):<fpage>194</fpage>&#8211;<lpage>204</lpage>. doi:<pub-id pub-id-type="doi">10.7326/0003-4819-139-3-200308050-00009</pub-id><pub-id pub-id-type="pmid">12899587</pub-id></mixed-citation></ref><ref id="bvac185-B120"><label>120</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Soule</surname><given-names>SG</given-names></string-name>, <string-name name-style="western"><surname>Fahie-Wilson</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Tomlinson</surname><given-names>S</given-names></string-name></person-group>. <article-title>Failure of the short ACTH test to unequivocally diagnose long-standing symptomatic secondary hypoadrenalism</article-title>. <source>Clin Endocrinol (Oxf)</source>. <year>1996</year>;<volume>44</volume>(<issue>2</issue>):<fpage>137</fpage>&#8211;<lpage>140</lpage>. doi:<pub-id pub-id-type="doi">10.1046/j.1365-2265.1996.540363.x</pub-id><pub-id pub-id-type="pmid">8849565</pub-id></mixed-citation></ref><ref id="bvac185-B121"><label>121</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Streeten</surname><given-names>DHP</given-names></string-name>, <string-name name-style="western"><surname>Anderson</surname><given-names>GH</given-names><suffix>Jr</suffix></string-name>, <string-name name-style="western"><surname>Bonaventura</surname><given-names>MM</given-names></string-name></person-group>. <article-title>The potential for serious consequences from misinterpreting normal responses to the rapid adrenocorticotropin test</article-title>. <source>J Clin Endocrinol Metab</source>. <year>1996</year>;<volume>81</volume>(<issue>1</issue>):<fpage>285</fpage>&#8211;<lpage>290</lpage>. doi:<pub-id pub-id-type="doi">10.1210/jcem.81.1.8550765</pub-id><pub-id pub-id-type="pmid">8550765</pub-id></mixed-citation></ref><ref id="bvac185-B122"><label>122</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lindholm</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kehlet</surname><given-names>H</given-names></string-name></person-group>. <article-title>Re-evaluation of the clinical value of the 30 min ACTH test in assessing the hypothalamic-pituitary-adrenocortical function</article-title>. <source>Clin Endocrinol (Oxf)</source>. <year>1987</year>;<volume>26</volume>(<issue>1</issue>):<fpage>53</fpage>&#8211;<lpage>59</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1365-2265.1987.tb03638.x</pub-id><pub-id pub-id-type="pmid">3026692</pub-id></mixed-citation></ref><ref id="bvac185-B123"><label>123</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cunningham</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Moore</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>McKenna</surname><given-names>TJ</given-names></string-name></person-group>. <article-title>Normal cortisol response to corticotropin in patients with secondary adrenal failure</article-title>. <source>Arch Intern Med</source>. <year>1983</year>;<volume>143</volume>(<issue>12</issue>):<fpage>2276</fpage>&#8211;<lpage>2279</lpage>. doi:<pub-id pub-id-type="doi">10.1001/archinte.1983.00350120066016</pub-id><pub-id pub-id-type="pmid">6316866</pub-id></mixed-citation></ref><ref id="bvac185-B124"><label>124</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mukherjee</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Jacome De Castro</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kaltsas</surname><given-names>G</given-names></string-name>, <etal>et al</etal></person-group><article-title>A comparison of the insulin tolerance/glucagon test with the short ACTH stimulation test in the assessment of the hypothalamo-pituitary-adrenal axis in the early post-operative period after hypophysectomy</article-title>. <source>Clin Endocrinol (Oxf)</source>. <year>1997</year>;<volume>47</volume>(<issue>1</issue>):<fpage>51</fpage>&#8211;<lpage>60</lpage>. doi:<pub-id pub-id-type="doi">10.1046/j.1365-2265.1997.2151035.x</pub-id><pub-id pub-id-type="pmid">9302372</pub-id></mixed-citation></ref><ref id="bvac185-B125"><label>125</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>H&#228;gg</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Asplund</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Lithner</surname><given-names>F</given-names></string-name></person-group>. <article-title>Value of basal plasma cortisol assays in the assessment of pituitary-adrenal insufficiency</article-title>. <source>Clin Endocrinol (Oxf)</source>. <year>1987</year>;<volume>26</volume>(<issue>2</issue>):<fpage>221</fpage>&#8211;<lpage>226</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1365-2265.1987.tb00780.x</pub-id><pub-id pub-id-type="pmid">3311477</pub-id></mixed-citation></ref><ref id="bvac185-B126"><label>126</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Le Roux</surname><given-names>CW</given-names></string-name>, <string-name name-style="western"><surname>Meeran</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Alaghband-Zadeh</surname><given-names>J</given-names></string-name></person-group>. <article-title>Is a 0900-h serum cortisol useful prior to a short Synacthen test in outpatient assessment?</article-title><source>Ann Clin Biochem</source>. <year>2002</year>;<volume>39</volume>(<issue>2</issue>):<fpage>148</fpage>&#8211;<lpage>150</lpage>. doi:<pub-id pub-id-type="doi">10.1258/0004563021901919</pub-id><pub-id pub-id-type="pmid">11930947</pub-id></mixed-citation></ref><ref id="bvac185-B127"><label>127</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Javorsky</surname><given-names>BR</given-names></string-name>, <string-name name-style="western"><surname>Raff</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Carroll</surname><given-names>TB</given-names></string-name>, <etal>et al</etal></person-group><article-title>New cutoffs for the biochemical diagnosis of adrenal insufficiency after ACTH stimulation using specific cortisol assays</article-title>. <source>J Endocr Soc</source>. <year>2021</year>;<volume>5</volume>(<issue>4</issue>):<fpage>bvab022</fpage>. doi:<pub-id pub-id-type="doi">10.1210/jendso/bvab022</pub-id><pub-id pub-id-type="pmid">33768189</pub-id><pub-id pub-id-type="pmcid">PMC7975762</pub-id></mixed-citation></ref><ref id="bvac185-B128"><label>128</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ueland</surname><given-names>GA</given-names></string-name>, <string-name name-style="western"><surname>Methlie</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>&#216;ksnes</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group><article-title>The short cosyntropin test revisited: new normal reference range using LC-MS/MS</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2018</year>;<volume>103</volume>(<issue>4</issue>):<fpage>1696</fpage>&#8211;<lpage>1703</lpage>. doi:<pub-id pub-id-type="doi">10.1210/jc.2017-02602</pub-id><pub-id pub-id-type="pmid">29452421</pub-id></mixed-citation></ref><ref id="bvac185-B129"><label>129</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Husni</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Abusamaan</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Dinparastisaleh</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Sokoll</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Salvatori</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Hamrahian</surname><given-names>AH</given-names></string-name></person-group>. <article-title>Cortisol values during the standard-dose cosyntropin stimulation test: personal experience with Elecsys cortisol II assay</article-title>. <source>Front Endocrinol (Lausanne)</source>. <year>2022</year>;<volume>13</volume>:<comment>978238</comment>. doi:<pub-id pub-id-type="doi">10.3389/fendo.2022.978238</pub-id><pub-id pub-id-type="pmcid">PMC9433864</pub-id><pub-id pub-id-type="pmid">36060940</pub-id></mixed-citation></ref><ref id="bvac185-B130"><label>130</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Grassi</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Morelli</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Ceriotti</surname><given-names>F</given-names></string-name>, <etal>et al</etal></person-group><article-title>Minding the gap between cortisol levels measured with second-generation assays and current diagnostic thresholds for the diagnosis of adrenal insufficiency: a single-center experience</article-title>. <source>Hormones</source>. <year>2020</year>;<volume>19</volume>(<issue>3</issue>):<fpage>425</fpage>&#8211;<lpage>431</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s42000-020-00185-y</pub-id><pub-id pub-id-type="pmid">32222957</pub-id><pub-id pub-id-type="pmcid">PMC7426310</pub-id></mixed-citation></ref><ref id="bvac185-B131"><label>131</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nasrallah</surname><given-names>MP</given-names></string-name>, <string-name name-style="western"><surname>Arafah</surname><given-names>BM</given-names></string-name></person-group>. <article-title>The value of dehydroepiandrosterone sulfate measurements in the assessment of adrenal function</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2003</year>;<volume>88</volume>(<issue>11</issue>):<fpage>5293</fpage>&#8211;<lpage>5298</lpage>. doi:<pub-id pub-id-type="doi">10.1210/jc.2003-030449</pub-id><pub-id pub-id-type="pmid">14602764</pub-id></mixed-citation></ref><ref id="bvac185-B132"><label>132</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Iii</surname><given-names>RFL</given-names></string-name>, <string-name name-style="western"><surname>Hechenbleikner</surname><given-names>EM</given-names></string-name>, <string-name name-style="western"><surname>Ha</surname><given-names>C</given-names></string-name>, <etal>et al</etal></person-group><article-title>Perioperative glucocorticoid prescribing habits in patients with inflammatory bowel disease: a call for standardization</article-title>. <source>JAMA Surg</source>. <year>2014</year>;<volume>149</volume>(<issue>5</issue>):<fpage>459</fpage>&#8211;<lpage>466</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamasurg.2013.5278</pub-id><pub-id pub-id-type="pmid">24647868</pub-id></mixed-citation></ref><ref id="bvac185-B133"><label>133</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Glowniak</surname><given-names>JV</given-names></string-name>, <string-name name-style="western"><surname>Loriaux</surname><given-names>DL</given-names></string-name></person-group>. <article-title>A double-blind study of perioperative steroid requirements in secondary adrenal insufficiency</article-title>. <source>Surgery</source>. <year>1997</year>;<volume>121</volume>(<issue>2</issue>):<fpage>123</fpage>&#8211;<lpage>129</lpage>. doi:<pub-id pub-id-type="doi">10.1016/s0039-6060(97)90280-4</pub-id><pub-id pub-id-type="pmid">9037222</pub-id></mixed-citation></ref><ref id="bvac185-B134"><label>134</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zaghiyan</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Melmed</surname><given-names>GY</given-names></string-name>, <string-name name-style="western"><surname>Berel</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Ovsepyan</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Murrell</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Fleshner</surname><given-names>P</given-names></string-name></person-group>. <article-title>A prospective, randomized, noninferiority trial of steroid dosing after major colorectal surgery</article-title>. <source>Ann Surg</source>. <year>2014</year>;<volume>259</volume>(<issue>1</issue>):<fpage>32</fpage>&#8211;<lpage>37</lpage>. doi:<pub-id pub-id-type="doi">10.1097/SLA.0b013e318297adca</pub-id><pub-id pub-id-type="pmid">23774314</pub-id></mixed-citation></ref><ref id="bvac185-B135"><label>135</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Thomason</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Girdler</surname><given-names>NM</given-names></string-name>, <string-name name-style="western"><surname>Kendall-Taylor</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Wastell</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Weddel</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Seymour</surname><given-names>RA</given-names></string-name></person-group>. <article-title>An investigation into the need for supplementary steroids in organ transplant patients undergoing gingival surgery: a double-blind, split-mouth, cross-over study</article-title>. <source>J Clin Periodontol</source>. <year>1999</year>;<volume>26</volume>(<issue>9</issue>):<fpage>577</fpage>&#8211;<lpage>582</lpage>. doi:<pub-id pub-id-type="doi">10.1034/j.1600-051x.1999.260903.x</pub-id><pub-id pub-id-type="pmid">10487307</pub-id></mixed-citation></ref><ref id="bvac185-B136"><label>136</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Solem</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Lund</surname><given-names>I</given-names></string-name></person-group>. <article-title>Prophylaxis with corticosteroids in surgical patients receiving cortisone</article-title>. <source>Acta Anaesthesiol Scand</source>. <year>1962</year>;<volume>6</volume>(<issue>2</issue>):<fpage>99</fpage>&#8211;<lpage>105</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1399-6576.1962.tb00108.x</pub-id><pub-id pub-id-type="pmid">13914933</pub-id></mixed-citation></ref><ref id="bvac185-B137"><label>137</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lloyd</surname><given-names>EL</given-names></string-name></person-group>. <article-title>A rational regimen for perioperative steroid supplements and a clinical assessment of the requirement</article-title>. <source>Ann R Coll Surg Engl</source>. <year>1981</year>;<volume>63</volume>(<issue>1</issue>):<fpage>54</fpage>&#8211;<lpage>57</lpage>.<pub-id pub-id-type="pmid">7247263</pub-id><pub-id pub-id-type="pmcid">PMC2493881</pub-id></mixed-citation></ref><ref id="bvac185-B138"><label>138</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bromberg</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Alfrey</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Barker</surname><given-names>C</given-names></string-name>, <etal>et al</etal></person-group><article-title>Adrenal suppression and steroid supplementation in renal transplant recipients</article-title>. <source>Transplantation</source>. <year>1991</year>;<volume>51</volume>(<issue>2</issue>):<fpage>358</fpage>&#8211;<lpage>390</lpage>. doi:<pub-id pub-id-type="doi">10.1097/00007890-199102000-00023</pub-id><pub-id pub-id-type="pmid">1847249</pub-id></mixed-citation></ref><ref id="bvac185-B139"><label>139</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shapiro</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Carroll</surname><given-names>PB</given-names></string-name>, <string-name name-style="western"><surname>Tzakis</surname><given-names>AG</given-names></string-name>, <string-name name-style="western"><surname>Cemaj</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Lopatin</surname><given-names>WB</given-names></string-name>, <string-name name-style="western"><surname>Nakazato</surname><given-names>P</given-names></string-name></person-group>. <article-title>Adrenal reserve in renal transplant recipients with cyclosporine, azathioprine and prednisone immunosuppression</article-title>. <source>Transplantation</source>. <year>1990</year>;<volume>49</volume>(<issue>5</issue>):<fpage>1011</fpage>&#8211;<lpage>1013</lpage>. doi:<pub-id pub-id-type="doi">10.1097/00007890-199005000-00039</pub-id><pub-id pub-id-type="pmid">2336689</pub-id></mixed-citation></ref><ref id="bvac185-B140"><label>140</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Friedman</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Schiff</surname><given-names>CF</given-names></string-name>, <string-name name-style="western"><surname>Bromberg</surname><given-names>JS</given-names></string-name></person-group>. <article-title>Use of supplemental steroids in patients having orthopaedic operations</article-title>. <source>J Bone Jt Surg</source>, <source>Ser A</source>. <year>1995</year>;<volume>77</volume>(<issue>12</issue>):<fpage>1801</fpage>&#8211;<lpage>1806</lpage>. doi:<pub-id pub-id-type="doi">10.2106/00004623-199512000-00002</pub-id><pub-id pub-id-type="pmid">8550646</pub-id></mixed-citation></ref><ref id="bvac185-B141"><label>141</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mathis</surname><given-names>AS</given-names></string-name>, <string-name name-style="western"><surname>Shah</surname><given-names>NK</given-names></string-name>, <string-name name-style="western"><surname>Mulgaonkar</surname><given-names>S</given-names></string-name></person-group>. <article-title>Stress dose steroids in renal transplant patients undergoing lymphocele surgery</article-title>. <source>Transplant Proc</source>. <year>2004</year>;<volume>36</volume>(<issue>10</issue>):<fpage>3042</fpage>&#8211;<lpage>3045</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.transproceed.2004.10.068</pub-id><pub-id pub-id-type="pmid">15686690</pub-id></mixed-citation></ref><ref id="bvac185-B142"><label>142</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Udelsman</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Ramp</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Gallucci</surname><given-names>WT</given-names></string-name>, <etal>et al</etal></person-group><article-title>Adaptation during surgical stress. A reevaluation of the role of glucocorticoids</article-title>. <source>J Clin Invest</source>. <year>1986</year>;<volume>77</volume>(<issue>4</issue>):<fpage>1377</fpage>&#8211;<lpage>1381</lpage>. doi:<pub-id pub-id-type="doi">10.1172/JCI112443</pub-id><pub-id pub-id-type="pmid">3958189</pub-id><pub-id pub-id-type="pmcid">PMC424500</pub-id></mixed-citation></ref><ref id="bvac185-B143"><label>143</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bromberg</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Baliga</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Cofer</surname><given-names>JB</given-names></string-name>, <string-name name-style="western"><surname>Rajagopalan</surname><given-names>PR</given-names></string-name>, <string-name name-style="western"><surname>Friedman</surname><given-names>RJ</given-names></string-name></person-group>. <article-title>Stress steroids are not required for renal allograft and undergoing operation</article-title>. <source>J Am Coll Surg</source>. <year>1995</year>;<volume>180</volume>(<issue>5</issue>):<fpage>523</fpage>&#8211;<lpage>536</lpage>.<pub-id pub-id-type="pmid">7749527</pub-id></mixed-citation></ref><ref id="bvac185-B144"><label>144</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zaghiyan</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Melmed</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Murrell</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Fleshner</surname><given-names>P</given-names></string-name></person-group>. <article-title>Are high-dose perioperative steroids necessary in patients undergoing colorectal surgery treated with steroid therapy within the past 12 months?</article-title><source>Am Surg</source>. <year>2011</year>;<volume>77</volume>(<issue>10</issue>):<fpage>1295</fpage>&#8211;<lpage>1299</lpage>. doi:<pub-id pub-id-type="doi">10.1177/000313481107701004</pub-id><pub-id pub-id-type="pmid">22127073</pub-id></mixed-citation></ref><ref id="bvac185-B145"><label>145</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zaghiyan</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Melmed</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Murrell</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Fleshner</surname><given-names>P</given-names></string-name></person-group>. <article-title>Safety and feasibility of using low-dose perioperative intravenous steroids in inflammatory bowel disease patients undergoing major colorectal surgery: a pilot study</article-title>. <source>Surg (United States)</source>. <year>2012</year>;<volume>152</volume>(<issue>2</issue>):<fpage>158</fpage>&#8211;<lpage>163</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.surg.2012.02.019</pub-id><pub-id pub-id-type="pmid">22503320</pub-id></mixed-citation></ref><ref id="bvac185-B146"><label>146</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zaghiyan</surname><given-names>KN</given-names></string-name>, <string-name name-style="western"><surname>Murrell</surname><given-names>Z</given-names></string-name>, <etal>et al</etal></person-group><article-title>High-dose perioperative corticosteroids in steroid-treated patients undergoing major colorectal surgery: necessary or overkill?</article-title><source>Am J Surg</source>. <year>2012</year>;<volume>204</volume>(<issue>4</issue>):<fpage>481</fpage>&#8211;<lpage>486</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.amjsurg.2011.09.036</pub-id><pub-id pub-id-type="pmid">22748293</pub-id></mixed-citation></ref><ref id="bvac185-B147"><label>147</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Aytac</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Londono</surname><given-names>JMR</given-names></string-name>, <string-name name-style="western"><surname>Erem</surname><given-names>HH</given-names></string-name>, <string-name name-style="western"><surname>Vogel</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Costedio</surname><given-names>MM</given-names></string-name></person-group>. <article-title>Impact of stress dose steroids on the outcomes of restorative proctocolectomy in patients with ulcerative colitis</article-title>. <source>Dis Colon Rectum</source>. <year>2013</year>;<volume>56</volume>(<issue>11</issue>):<fpage>1253</fpage>&#8211;<lpage>1258</lpage>. doi:<pub-id pub-id-type="doi">10.1097/DCR.0b013e3182a180b7</pub-id><pub-id pub-id-type="pmid">24105000</pub-id></mixed-citation></ref><ref id="bvac185-B148"><label>148</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jasani</surname><given-names>MK</given-names></string-name>, <string-name name-style="western"><surname>Freeman</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Boyle</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Downie</surname><given-names>WW</given-names></string-name>, <string-name name-style="western"><surname>Wright</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Buchanan</surname><given-names>WW</given-names></string-name></person-group>. <article-title>Cardiovascular and plasma cortisol responses to surgery in corticosteroid-treated R.A. patients</article-title>. <source>Acta Rheumatol Scand</source>. <year>1968</year>;<volume>14</volume>(<issue>1-4</issue>):<fpage>65</fpage>&#8211;<lpage>70</lpage>. doi:<pub-id pub-id-type="doi">10.3109/rhe1.1968.14.issue-1-4.07</pub-id><pub-id pub-id-type="pmid">5649435</pub-id></mixed-citation></ref><ref id="bvac185-B149"><label>149</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Woodcock</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Barker</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Daniel</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group><article-title>Guidelines for the management of glucocorticoids during the peri-operative period for patients with adrenal insufficiency guidelines from the Association of Anaesthetists, the Royal College of Physicians and the Society for Endocrinology UK</article-title>. <source>Anaesthesia</source>. <year>2020</year>;<volume>75</volume>(<issue>5</issue>):<fpage>654</fpage>&#8211;<lpage>663</lpage>. doi:<pub-id pub-id-type="doi">10.1111/anae.14963</pub-id><pub-id pub-id-type="pmid">32017012</pub-id></mixed-citation></ref><ref id="bvac185-B150"><label>150</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Borresen</surname><given-names>SW</given-names></string-name>, <string-name name-style="western"><surname>Klose</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Glintborg</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Watt</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Andersen</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Feldt-Rasmussen</surname><given-names>U</given-names></string-name></person-group>. <article-title>Approach to the patient with glucocorticoid-induced adrenal insufficiency</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2022</year>;<volume>107</volume>(<issue>7</issue>):<fpage>2065</fpage>&#8211;<lpage>2076</lpage>. doi:<pub-id pub-id-type="doi">10.1210/clinem/dgac151</pub-id><pub-id pub-id-type="pmid">35302603</pub-id></mixed-citation></ref><ref id="bvac185-B151"><label>151</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kehlet</surname><given-names>H</given-names></string-name></person-group>. <article-title>A rational approach to dosage and preparation of parenteral glucocorticoid substitution therapy during surgical procedures: a short review</article-title>. <source>Acta Anaesthesiol Scand</source>. <year>1975</year>;<volume>19</volume>(<issue>4</issue>):<fpage>260</fpage>&#8211;<lpage>264</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1399-6576.1975.tb05182.x</pub-id><pub-id pub-id-type="pmid">1189879</pub-id></mixed-citation></ref><ref id="bvac185-B152"><label>152</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nicholson</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Burrin</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Hall</surname><given-names>GM</given-names></string-name></person-group>. <article-title>Peri-operative steroid supplementation</article-title>. <source>Anaesthesia</source>. <year>1999</year>;<volume>54</volume>(<issue>4</issue>):<fpage>507</fpage>. doi:<pub-id pub-id-type="doi">10.1046/j.1365-2044.1998.00578.x</pub-id><pub-id pub-id-type="pmid">10023279</pub-id></mixed-citation></ref><ref id="bvac185-B153"><label>153</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jabbour</surname><given-names>SA</given-names></string-name></person-group>. <article-title>Steroids and the surgical patient</article-title>. <source>Med Clin North Am</source>. <year>2001</year>;<volume>85</volume>(<issue>5</issue>):<fpage>1311</fpage>&#8211;<lpage>1317</lpage>. doi:<pub-id pub-id-type="doi">10.1016/s0025-7125(05)70379-5</pub-id><pub-id pub-id-type="pmid">11565501</pub-id></mixed-citation></ref><ref id="bvac185-B154"><label>154</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jung</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Inder</surname><given-names>WJ</given-names></string-name></person-group>. <article-title>Management of adrenal insufficiency during the stress of medical illness and surgery</article-title>. <source>Med J Aust</source>. <year>2008</year>;<volume>188</volume>(<issue>7</issue>):<fpage>409</fpage>&#8211;<lpage>413</lpage>. doi:<pub-id pub-id-type="doi">10.5694/j.1326-5377.2008.tb01686.x</pub-id><pub-id pub-id-type="pmid">18393745</pub-id></mixed-citation></ref><ref id="bvac185-B155"><label>155</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fleager</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Yao</surname><given-names>J</given-names></string-name></person-group>. <article-title>Perioperative steroid dosing in patients receiving chronic oral steroids, undergoing outpatient hand surgery</article-title>. <source>J Hand Surg Am</source>. <year>2010</year>;<volume>35</volume>(<issue>2</issue>):<fpage>316</fpage>&#8211;<lpage>318</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jhsa.2009.10.001</pub-id><pub-id pub-id-type="pmid">19942359</pub-id></mixed-citation></ref><ref id="bvac185-B156"><label>156</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Reidy</surname><given-names>AB</given-names></string-name>, <string-name name-style="western"><surname>Saatee</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Collard</surname><given-names>CD</given-names></string-name></person-group>. <article-title>Perioperative steroid management</article-title>. <source>Anesthesiology</source>. <year>2017</year>;<volume>127</volume>(<issue>1</issue>):<fpage>166</fpage>&#8211;<lpage>172</lpage>. doi:<pub-id pub-id-type="doi">10.1097/ALN.0000000000001659</pub-id><pub-id pub-id-type="pmid">28452806</pub-id></mixed-citation></ref><ref id="bvac185-B157"><label>157</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>de Lange</surname><given-names>DW</given-names></string-name>, <string-name name-style="western"><surname>Kars</surname><given-names>M</given-names></string-name></person-group>. <article-title>Perioperative glucocorticosteroid supplementation is not supported by evidence</article-title>. <source>Eur J Intern Med</source>. <year>2008</year>;<volume>19</volume>(<issue>6</issue>):<fpage>461</fpage>&#8211;<lpage>467</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ejim.2007.12.004</pub-id><pub-id pub-id-type="pmid">18848181</pub-id></mixed-citation></ref><ref id="bvac185-B158"><label>158</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Marik</surname><given-names>PE</given-names></string-name>, <string-name name-style="western"><surname>Varon</surname><given-names>J</given-names></string-name></person-group>. <article-title>Requirement of perioperative stress doses of corticosteroids</article-title>. <source>Arch Surg</source>. <year>2008</year>;<volume>143</volume>(<issue>12</issue>):<fpage>1222</fpage>&#8211;<lpage>1226</lpage>. doi:<pub-id pub-id-type="doi">10.1001/archsurg.143.12.1222</pub-id><pub-id pub-id-type="pmid">19075176</pub-id></mixed-citation></ref><ref id="bvac185-B159"><label>159</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kelly</surname><given-names>KN</given-names></string-name>, <string-name name-style="western"><surname>Domajnko</surname><given-names>B</given-names></string-name></person-group>. <article-title>Perioperative stress-dose steroids</article-title>. <source>Clin Colon Rectal Surg</source>. <year>2013</year>;<volume>26</volume>(<issue>3</issue>):<fpage>163</fpage>&#8211;<lpage>167</lpage>. doi:<pub-id pub-id-type="doi">10.1055/s-0033-1351132</pub-id><pub-id pub-id-type="pmid">24436668</pub-id><pub-id pub-id-type="pmcid">PMC3747280</pub-id></mixed-citation></ref><ref id="bvac185-B160"><label>160</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hicks</surname><given-names>CW</given-names></string-name>, <string-name name-style="western"><surname>Wick</surname><given-names>EC</given-names></string-name>, <string-name name-style="western"><surname>Salvatori</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Ha</surname><given-names>CY</given-names></string-name></person-group>. <article-title>Perioperative corticosteroid management for patients with inflammatory bowel disease</article-title>. <source>Inflamm Bowel Dis</source>. <year>2015</year>;<volume>21</volume>(<issue>1</issue>):<fpage>221</fpage>&#8211;<lpage>228</lpage>. doi:<pub-id pub-id-type="doi">10.1097/MIB.0000000000000185</pub-id><pub-id pub-id-type="pmid">25208109</pub-id></mixed-citation></ref><ref id="bvac185-B161"><label>161</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>MacKenzie</surname><given-names>CR</given-names></string-name>, <string-name name-style="western"><surname>Goodman</surname><given-names>SM</given-names></string-name></person-group>. <article-title>Stress dose steroids: myths and perioperative medicine</article-title>. <source>Curr Rheumatol Rep</source>. <year>2016</year>;<volume>18</volume>(<issue>7</issue>):<fpage>1</fpage>&#8211;<lpage>5</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11926-016-0595-7</pub-id><pub-id pub-id-type="pmid">27351679</pub-id></mixed-citation></ref><ref id="bvac185-B162"><label>162</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Khazen</surname><given-names>BF</given-names></string-name>, <string-name name-style="western"><surname>El-Hussuna</surname><given-names>A</given-names></string-name></person-group>. <article-title>The use of a perioperative supra-physiological dose of glucocorticoid is not supported by evidence&#8212;a systematic review</article-title>. <source>Dan Med J</source>. <year>2018</year>;<volume>65</volume>(<issue>6</issue>):<fpage>A5488</fpage>.<pub-id pub-id-type="pmid">29886882</pub-id></mixed-citation></ref><ref id="bvac185-B163"><label>163</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Manou-Stathopoulou</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Korbonits</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ackland</surname><given-names>GL</given-names></string-name></person-group>. <article-title>Redefining the perioperative stress response: a narrative review</article-title>. <source>Br J Anaesth</source>. <year>2019</year>;<volume>123</volume>(<issue>5</issue>):<fpage>570</fpage>&#8211;<lpage>583</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.bja.2019.08.011</pub-id><pub-id pub-id-type="pmid">31547969</pub-id></mixed-citation></ref><ref id="bvac185-B164"><label>164</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Arafah</surname><given-names>BM</given-names></string-name></person-group>. <article-title>Perioperative glucocorticoid therapy for patients with adrenal insufficiency: dosing based on pharmacokinetic data</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2020</year>;<volume>105</volume>(<issue>3</issue>):<fpage>753</fpage>&#8211;<lpage>761</lpage>. doi:<pub-id pub-id-type="doi">10.1210/clinem/dgaa042</pub-id><pub-id pub-id-type="pmid">31996925</pub-id></mixed-citation></ref><ref id="bvac185-B165"><label>165</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Salvatori</surname><given-names>R</given-names></string-name></person-group>. <article-title>Perioperative glucocorticoid therapy in adrenal insufficiency: what is the correct dose?</article-title><source>J Clin Endocrinol Metab</source>. <year>2020</year>;<volume>105</volume>(<issue>5</issue>):<fpage>2078</fpage>&#8211;<lpage>2079</lpage>. doi:<pub-id pub-id-type="doi">10.1210/clinem/dgaa102</pub-id><pub-id pub-id-type="pmid">32112559</pub-id></mixed-citation></ref><ref id="bvac185-B166"><label>166</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bornstein</surname><given-names>SR</given-names></string-name>, <string-name name-style="western"><surname>Allolio</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Arlt</surname><given-names>W</given-names></string-name>, <etal>et al</etal></person-group><article-title>Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society clinical practice guideline</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2016</year>;<volume>101</volume>(<issue>2</issue>):<fpage>364</fpage>&#8211;<lpage>389</lpage>. doi:<pub-id pub-id-type="doi">10.1210/jc.2015-1710</pub-id><pub-id pub-id-type="pmid">26760044</pub-id><pub-id pub-id-type="pmcid">PMC4880116</pub-id></mixed-citation></ref><ref id="bvac185-B167"><label>167</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Monticone</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Auchus</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Rainey</surname><given-names>WE</given-names></string-name></person-group>. <article-title>Adrenal disorders in pregnancy</article-title>. <source>Nat Rev Endocrinol</source>. <year>2012</year>;<volume>8</volume>(<issue>11</issue>):<fpage>668</fpage>&#8211;<lpage>678</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nrendo.2012.155</pub-id><pub-id pub-id-type="pmid">22965163</pub-id></mixed-citation></ref><ref id="bvac185-B168"><label>168</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Petersenn</surname><given-names>S</given-names></string-name></person-group>. <article-title>Secondary adrenal insufficiency in pregnancy: any differences?</article-title><source>Minerva Endocrinol</source>. <year>2018</year>;<volume>43</volume>(<issue>4</issue>):<fpage>446</fpage>&#8211;<lpage>450</lpage>. doi:<pub-id pub-id-type="doi">10.23736/S0391-1977.18.02840-7</pub-id><pub-id pub-id-type="pmid">29546743</pub-id></mixed-citation></ref></ref-list><glossary><title>Abbreviations</title><def-list><def-item><term>AI</term><def><p>adrenal insufficiency</p></def></def-item><def-item><term>CST</term><def><p>cosyntropin stimulation test</p></def></def-item><def-item><term>DHEA-S</term><def><p>dehydroepiandrosterone sulfate</p></def></def-item><def-item><term>GC</term><def><p>glucocorticoid</p></def></def-item><def-item><term>HPA</term><def><p>hypothalamic-pituitary-adrenal</p></def></def-item><def-item><term>IBD</term><def><p>inflammatory bowel disease</p></def></def-item><def-item><term>RCT</term><def><p>randomized controlled trial</p></def></def-item></def-list></glossary></back></article></pmc-articleset>